# EDGAR Filing Document

**Accession Number:** 0000103145
**File Stem:** 0001104659-25-107052
**Filing Date:** 2025-11
**Character Count:** 152568
**Document Hash:** a1ae6758196b06beb82e682a32bf4e83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-107052.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001104659-25-107052

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 78

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VEECO INSTRUMENTS INC
- **CENTRAL INDEX KEY:** 0000103145
- **STANDARD INDUSTRIAL CLASSIFICATION:** SPECIAL INDUSTRY MACHINERY, NEC [3559]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 112989601
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-16244
- **FILM NUMBER:** 251454559

**BUSINESS ADDRESS:**
- **STREET 1:** TERMINAL DRIVE
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803
- **BUSINESS PHONE:** 516 677-0200

**MAIL ADDRESS:**
- **STREET 1:** TERMINAL DRIVE
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VACUUM ELECTRONIC MANUFACTURING CORP
- **DATE OF NAME CHANGE:** 19700408

?xml version='1.0' encoding='ASCII'? VEECO INSTRUMENTS INC._September 30, 2025

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended September 30, 2025**

**OR**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission file number 0-16244**

**VEECO INSTRUMENTS INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** |  | **11-2989601** |
| (State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification No.) |
| **Terminal DrivePlainview, New York** |  | **11803** |
| (Address of Principal Executive Offices) |  | (Zip Code) |

---

Registrant's telephone number, including area code:

**(516) 677-0200**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.01 per share** | **VECO** | **The NASDAQ Global Select Market** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes ☒ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;Large accelerated filer ☒ | &nbsp;&nbsp;Accelerated filer ☐ |
| &nbsp;&nbsp;Non-accelerated filer ☐ | &nbsp;&nbsp;Smaller reporting company ☐ |
|  | &nbsp;&nbsp;Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 30, 2025, there were 60,162,510 shares of the registrant's common stock outstanding.

------

[**Table of Contents**](#TOC)

**VEECO INSTRUMENTS INC.**

**INDEX**

---

| | |
|:---|:---|
| [Safe Harbor Statement](#SafeHarborStatement_940941) | 1 |
| [PART I—FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_642777) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1. Financial Statements](#Item1FinancialStatements_377663) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF) | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 3. Quantitative and Qualitative Disclosures about Market Risk](#Item3QuantitativeandQualitativeDisclosur) | 35 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 4. Controls and Procedures](#Item4ControlsandProcedures_183959) | 36 |
| [PART II—OTHER INFORMATION](#PARTIIOTHERINFORMATION_174374) | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1. Legal Proceedings](#Item1LegalProceedings_321234) | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1A. Risk Factors](#Item1ARiskFactors) | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities) | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 3. Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_376506) | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 4. Mine Safety Disclosures](#Item4MineSafetyDisclosures_741021) | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 5. Other Information](#Item5OtherInformation_241196) | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 6. Exhibits](#Item6Exhibits_919397) | 41 |
| [SIGNATURES](#SIGNATURES_882826) | 42 |

---

[**Table of Contents**](#TOC)

**Safe Harbor Statement**

This quarterly report on Form 10-Q (the "Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to Veeco Instruments Inc. (together with its consolidated subsidiaries, "Veeco," the "Company," "Registrant," "we," "our," or "us," unless the context indicates otherwise) that are based on management's expectations, estimates, projections, and assumptions. When used in this Report, the words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates," and variations of these words and similar expressions are intended to identify forward-looking statements. Discussions containing such forward-looking statements may be found in Part I - Items 1, 2, and 3 hereof, as well as within this Report generally.

In addition, the preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates and assumptions are based on knowledge of current events and planned actions to be undertaken in the future, they may ultimately differ from actual results. Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. All estimates and assumptions are subject to a number of risks and uncertainties that could cause actual results to differ materially from these estimates and assumptions.

Forward-looking statements in this discussion include, but are not limited to, those regarding anticipated growth and trends in our business and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for the current and future periods, and other statements that are not historical facts. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation, those set forth under the heading "Risk Factors" in Part 1, Item 1A of our 2024 Form 10-K, and the following:

● Changes in U.S. and foreign trade policies, including the recent imposition of tariffs, together with the prospect of additional foreign and domestic trade restrictions;

● Risks associated with operating a global business, including ongoing trade disputes between the U.S. and China;

● An inability to obtain required export licenses for the sale of our products;

● Unfavorable market conditions;

● Significant third party competition;

● Risks associated with operating in industries characterized by rapid technological change;

● Our dependency on the demand for consumer electronic products and automobiles;

● Our concentrated customer base;

● The cyclicality of the industries we serve;

● A failure to estimate customer demand accurately;

● Our reliance on a limited number of suppliers, some of whom are our sole source for particular components;

[**Table of Contents**](#TOC)

● A failure to successfully manage our outsourcing activities or a failure of our outsourcing partners to perform as anticipated;

● The timing of our orders, shipments, and revenue recognition;

● Our long and unpredictable sales cycles;

● Customer order cancellations or modifications;

● Risks associated with business combinations, acquisitions, strategic investments and divestitures;

● Risks associated with global regulatory requirements;

● Disruptions in our information technology systems or data security incidents;

● An inability to effectively enforce and protect our intellectual property rights;

● Claims of intellectual property infringement by others;

● Tightening credit markets;

● Foreign currency exchange risks;

● Asset impairment charges;

● Changes in accounting pronouncements or taxation rules, practices, or rates;

● Restrictions, covenants and repurchase provisions appearing in our current debt facilities;

● Possible impairment to our ability to utilize our research and development credits carryforwards caused by the issuance of common stock upon the conversion of the Notes;

● Our capped call transactions, which may affect the value of our common stock;

● Delays in or failure to complete the Merger (as defined herein), whether due to an inability by either party to satisfy one or more conditions to closing, including an inability to obtain required shareholder approvals or certain regulatory approvals, the occurrence of events or changes in circumstances that give rise to the termination of the Merger Agreement (as defined herein) by either party, or otherwise;

● Risks related to the pendency of the Merger and its effect on our business, financial condition, results of operations, cash flows and stock price;

● An inability to attract, retain, and motivate employees, including as a result of the Merger;

● Diversion of management time and attention from ordinary course business operations to the Merger and other potential disruptions to our business relating thereto;

● Risks associated with non-compliance with environmental, health, and safety regulations ;

● Environmental, social and governance goals, strategies and requirements which could be costly to implement and which expose us to risks associated with failures to comply;

[**Table of Contents**](#TOC)

● Measures adopted by Veeco which may have anti-takeover effects or which may make an acquisition of our Company by another company more difficult; and

● Other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q, and 8-K, and from time-to-time in our other SEC reports.

All forward-looking statements speak only to management's expectations, estimates, projections and assumptions as of the date of this filing or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this filing.

[**Table of Contents**](#TOC)

**PART I**—**FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Balance Sheets**

(in thousands, except share amounts)

---

| | | |
|:---|:---|:---|
|  | **September 30,** <br>**2025** | **December 31,** <br>**2024** |
| **Assets** | (unaudited) |  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $193192 | $145595 |
| &nbsp;&nbsp;Restricted cash | 30 | 224 |
| &nbsp;&nbsp;Short-term investments | 176130 | 198719 |
| &nbsp;&nbsp;Accounts receivable, net | 116471 | 96834 |
| &nbsp;&nbsp;Contract assets | 31067 | 37109 |
| &nbsp;&nbsp;Inventories | 263311 | 246735 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 30133 | 39316 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 810334 | 764532 |
| Property, plant, and equipment, net | 109120 | 113789 |
| Operating lease right-of-use assets | 25275 | 26503 |
| Intangible assets, net | 6418 | 8832 |
| Goodwill | 214964 | 214964 |
| Deferred income taxes | 120120 | 120191 |
| Other assets | 3680 | 2766 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $1289911 | $1251577 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | $43580 | $43519 |
| &nbsp;&nbsp;Accrued expenses and other current liabilities | 50220 | 55195 |
| &nbsp;&nbsp;Contract liabilities | 57054 | 64986 |
| &nbsp;&nbsp;Income taxes payable | 332 | 2086 |
| &nbsp;&nbsp;Current portion of long-term debt |  | 26496 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 151186 | 192282 |
| Deferred income taxes | 633 | 689 |
| Long-term debt | 225723 | 249702 |
| Long-term operating lease liabilities | 32644 | 34318 |
| Other liabilities | 3755 | 3816 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | 413941 | 480807 |
| Stockholders' equity: |  |  |
| Preferred stock, $0.01 par value; 500,000 shares authorized; no shares issued and outstanding. |  |  |
| Common stock, $0.01 par value; 120,000,000 shares authorized; 60,159,113 shares issued and outstanding at September 30, 2025 and 56,827,915 shares issued and outstanding at December 31, 2024 | 602 | 569 |
| Additional paid-in capital | 1297743 | 1227134 |
| Accumulated deficit | (424179) | (458455) |
| Accumulated other comprehensive income | 1804 | 1522 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity** | 875970 | 770770 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and stockholders' equity** | $1289911 | $1251577 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Statements of Operations**

(in thousands, except per share amounts)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| Net sales  | $165881 | $184807 | $499277 | $535170 |
| Cost of sales | 98178 | 105596 | 294380 | 305150 |
| Gross profit | 67703 | 79211 | 204897 | 230020 |
| Operating expenses, net: |  |  |  |  |
| &nbsp;&nbsp;Research and development | 28988 | 32216 | 89062 | 93554 |
| &nbsp;&nbsp;Selling, general, and administrative | 27263 | 25291 | 76218 | 74586 |
| &nbsp;&nbsp;Amortization of intangible assets | 771 | 1687 | 2413 | 5403 |
| &nbsp;&nbsp;Other operating expense (income), net | 127 | (4318) | 132 | (6625) |
| Total operating expenses, net | 57149 | 54876 | 167825 | 166918 |
| Operating income | 10554 | 24335 | 37072 | 63102 |
| &nbsp;&nbsp;Interest income | 3485 | 3204 | 10022 | 9643 |
| &nbsp;&nbsp;Interest expense | (2164) | (2881) | (6960) | (8266) |
| &nbsp;&nbsp;Other income (expense), net |  |  | (653) |  |
| Income before income taxes | 11875 | 24658 | 39481 | 64479 |
| &nbsp;&nbsp;Income tax expense | 1279 | 2707 | 5205 | 5730 |
| Net income | $10596 | $21951 | $34276 | $58749 |
| Income per common share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.18 | $0.39 | $0.58 | $1.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted  | $0.17 | $0.36 | $0.57 | $0.97 |
| Weighted average number of shares: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 60077 | 56410 | 58993 | 56256 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 60950 | 62654 | 60436 | 62103 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Statements of Comprehensive Income**

(in thousands)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| Net income | $10596 | $21951 | $34276 | $58749 |
| Other comprehensive income (loss), net of tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on available-for-sale securities | 140 | 277 | 231 | 172 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in currency translation adjustments | 4 | 105 | 51 | 70 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss), net of tax | 144 | 382 | 282 | 242 |
| Total comprehensive income | $10740 | $22333 | $34558 | $58991 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Statements of Cash Flows**

(in thousands)

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2024** |
| **Cash Flows from Operating Activities** |  |  |
| Net income | $34276 | $58749 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 15038 | 19161 |
| &nbsp;&nbsp;Non-cash interest expense | 833 | 935 |
| &nbsp;&nbsp;Deferred income taxes | 427 | 1885 |
| &nbsp;&nbsp;Share-based compensation expense | 28004 | 26774 |
| &nbsp;&nbsp;Changes in contingent consideration |  | (4775) |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;Accounts receivable and contract assets | (13607) | (35754) |
| &nbsp;&nbsp;Inventories  | (16576) | (3695) |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 4826 | (420) |
| &nbsp;&nbsp;Accounts payable and accrued expenses | (2586) | 12323 |
| &nbsp;&nbsp;Contract liabilities | (7932) | (37558) |
| &nbsp;&nbsp;Income taxes receivable and payable, net | 3401 | 1060 |
| &nbsp;&nbsp;Other, net | (1537) | (3255) |
| Net cash provided by (used in) operating activities | 44567 | 35430 |
| **Cash Flows from Investing Activities** |  |  |
| Capital expenditures | (12928) | (12934) |
| Proceeds from the sale of investments | 155343 | 116710 |
| Payments for purchases of investments | (130483) | (124639) |
| Proceeds from sale of productive assets |  | 2033 |
| Net cash provided by (used in) investing activities | 11932 | (18830) |
| **Cash Flows from Financing Activities** |  |  |
| Restricted stock tax withholdings | (6858) | (14875) |
| Repayment of convertible debt | (5229) |  |
| Debt issuance costs  | (885) |  |
| Contingent consideration payments |  | (1818) |
| Proceeds (net of tax withholdings) from option exercises and employee stock purchase plan | 3810 | 4368 |
| Net cash provided by (used in) financing activities | (9162) | (12325) |
| Effect of exchange rate changes on cash and cash equivalents | 66 | 91 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 47403 | 4366 |
| Cash, cash equivalents, and restricted cash - beginning of period | 145819 | 159120 |
| Cash, cash equivalents, and restricted cash - end of period | $193222 | $163486 |
| **Supplemental Disclosure of Cash Flow Information** |  |  |
| &nbsp;&nbsp;Interest paid | $4767 | $5480 |
| &nbsp;&nbsp;Net income taxes paid (refunded) | 70 | 2966 |
| **Non-cash activities** |  |  |
| &nbsp;&nbsp;Capital expenditures included in accounts payable and accrued expenses | 720 | 281 |
| &nbsp;&nbsp;Right-of-use assets obtained in exchange for lease obligations | 944 | 4695 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Note 1 — Basis of Presentation**

The accompanying unaudited Consolidated Financial Statements of Veeco have been prepared in accordance with U.S. GAAP as defined in Financial Accounting Standards Board ("FASB") Accounting Standards Codification 270 for interim financial information and with the instructions to Rule 10-01 of Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements as the interim information is an update of the information that was presented in Veeco's most recent annual financial statements. For further information, refer to Veeco's Consolidated Financial Statements and Notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2024 ("2024 Form 10-K"). In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal, recurring nature.

Veeco reports interim quarters on a 13-week basis ending on the last Sunday of each quarter. The fourth quarter always ends on the last day of the calendar year, December 31. The 2025 interim quarters end on March 30, June 29, and September 28, and the 2024 interim quarters end on March 31, June 30, and September 29. These interim quarters are reported as March 31, June 30, and September 30 in Veeco's interim consolidated financial statements.

The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on management's knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates.

*Accounting Standards Recently Adopted*

In December 2023, the FASB issued ASU 2023-09: *Improvements to Income Tax Disclosures (Topic 740)*. This amendment requires public entities annually to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of annual income tax disclosures. This authoritative guidance is effective for the Company's annual reporting periods beginning January 1, 2025. The amendments require increased annual disclosures on current and comparable reporting periods presented in annual company filings. The resulting new annual disclosure requirements will be reflected in the Company's 2025 report on Form 10-K.

In November 2024, the FASB issued ASU 2024-04, *Debt – Debt with Conversion and Other Options (Subtopic 470-20)* which clarifies the conditions in which induced conversion accounting applies to convertible debt by outlining three criteria that must be met for an entity to apply the induced conversion model. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2025 (and interim reporting periods within those annual reporting periods), with early adoption permitted. The Company has decided to adopt ASU 2024-04 on a prospective basis effective during the three and six months ended June 30, 2025, and has applied the amendments in this ASU to the repurchase of the 2027 Notes. Refer to Note 4 *Liabilities* for further details.

*Recent Accounting Standards Not Yet Adopted*

In November 2024, the FASB issued ASU 2024-03, "Disaggregation of Income Statements Expenses (Subtopic 220-40)," to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement's expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.

[**Table of Contents**](#TOC)

*Pending Merger with Axcelis Technologies, Inc.*

On September 30, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Axcelis Technologies, Inc., a Delaware corporation ("Axcelis"), and Victory Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Axcelis ("Merger Sub"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub will merge with and into Veeco (the "Merger"), with Veeco surviving as a wholly-owned subsidiary of Axcelis. See Note 10 *Subsequent Events* for additional information.

**Note 2 — Income Per Common Share**

Basic income per share is calculated by dividing net income by the weighted average number of shares outstanding during the period. Diluted income per share is calculated by dividing net income available to common shareholders by the weighted average number of shares used to calculate basic income per share plus the weighted average number of common share equivalents outstanding during the period. The dilutive effect of outstanding options to purchase common stock and share-based awards is considered in diluted income per share by application of the treasury stock method. The dilutive effect of performance share units is included in diluted income per common share if the performance targets have been achieved, or would have been achieved if the reporting date was the end of the contingency period. Finally, the Company includes the dilutive effect of shares issuable upon conversion of its Notes in the calculation of diluted income per share using the if-converted method. The Company must settle the principal amount of the 2029 Notes in cash, and has the option to settle any excess of the conversion value over the principal amount in any combination of cash or shares. As such, the Company only includes the excess shares that may be issuable above the principal amount of the 2029 Notes in the dilutive share count, if the effect would be dilutive.

The computations of basic and diluted income per share for the three and nine months ended September 30, 2025 and 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
|  | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* |
| **Numerator:**  |  |  |  |  |
| Net income | $10596 | $21951 | $34276 | $58749 |
| Interest expense associated with convertible notes |  | 515 | 378 | 1541 |
| Net income available to common shareholders | $10596 | $22466 | $34654 | $60290 |
| **Denominator:** |  |  |  |  |
| Basic weighted average shares outstanding | 60077 | 56410 | 58993 | 56256 |
| Effect of potentially dilutive share-based awards | 873 | 1606 | 552 | 1329 |
| Dilutive effect of convertible notes  |  | 4638 | 891 | 4518 |
| Diluted weighted average shares outstanding | 60950 | 62654 | 60436 | 62103 |
| **Net income per common share:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.18 | $0.39 | $0.58 | $1.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.17 | $0.36 | $0.57 | $0.97 |
| Potentially dilutive shares excluded from the diluted calculation as their effect would be antidilutive | 612 | 3 | 643 | 54 |
| Potential shares to be issued for settlement of the convertible notes excluded from the diluted calculation as their effect would be antidilutive  | N/A | N/A | 61 | N/A |

---

[**Table of Contents**](#TOC)

**Note 3 — Assets**

*Investments*

Short-term investments are generally classified as available-for-sale and reported at fair value, with unrealized gains and losses, net of tax, presented as a separate component of stockholders' equity under the caption "Accumulated other comprehensive income" in the Consolidated Balance Sheets. These securities may include U.S. treasuries, government agency securities, corporate debt, and commercial paper, all with maturities of greater than three months when purchased. All realized gains and losses and unrealized losses resulting from declines in fair value that are other than temporary are included in "Other operating expense (income), net" in the Consolidated Statements of Operations.

Fair value is the price that would be received for an asset or the amount paid to transfer a liability in an orderly transaction between market participants. Veeco classifies certain assets based on the following fair value hierarchy:

Level 1: Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly; and

Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Veeco has evaluated the estimated fair value of financial instruments using available market information and valuations as provided by third-party sources. The use of different market assumptions or estimation methodologies could have a significant effect on the estimated fair value amounts.

[**Table of Contents**](#TOC)

The following table presents the portion of Veeco's assets that were measured at fair value on a recurring basis at September 30, 2025 and December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **September 30, 2025** |  |  |  |  |
| &nbsp;&nbsp;**Cash equivalents** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Certificate of deposits and time deposits | $73753 | $— | $— | $73753 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market cash | 34387 |  |  | 34387 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $108140 | $— | $— | $108140 |
| &nbsp;&nbsp;**Short-term investments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasuries | $50791 | $— | $— | $50791 |
| &nbsp;&nbsp;&nbsp;&nbsp;Government agency securities |  | 50324 |  | 50324 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 75015 |  | 75015 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $50791 | $125339 | $— | $176130 |
| **December 31, 2024** |  |  |  |  |
| &nbsp;&nbsp;**Cash equivalents** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Certificate of deposits and time deposits | $66023 | $— | $— | $66023 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market cash | 15003 |  |  | 15003 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $81026 | $— | $— | $81026 |
| &nbsp;&nbsp;**Short-term investments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasuries | $84032 | $— | $— | $84032 |
| &nbsp;&nbsp;&nbsp;&nbsp;Government agency securities |  | 30167 |  | 30167 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 83051 |  | 83051 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 1469 |  | 1469 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $84032 | $114687 | $— | $198719 |

---

There were no transfers between fair value measurement levels during the three and nine months ended September 30, 2025.

At September 30, 2025 and December 31, 2024, the amortized cost and fair value of available-for-sale securities consist of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Amortized**<br>**Cost** | **Gross**<br>**Unrealized**<br>**Gains** | **Gross**<br>**Unrealized**<br>**Losses** | <br>**Estimated**<br>**Fair Value** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **September 30, 2025** |  |  |  |  |
| &nbsp;&nbsp;U.S. treasuries | $50760 | $33 | $(2) | $50791 |
| &nbsp;&nbsp;Government agency securities | 50319 | 30 | (25) | 50324 |
| &nbsp;&nbsp;Corporate debt | 74962 | 70 | (17) | 75015 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  | $176041 | $133 | $(44) | $176130 |
| **December 31, 2024** |  |  |  |  |
| &nbsp;&nbsp;U.S. treasuries | $84008 | $45 | $(21) | $84032 |
| &nbsp;&nbsp;Government agency securities | 30244 | 13 | (90) | 30167 |
| &nbsp;&nbsp;Corporate debt | 83209 | 17 | (175) | 83051 |
| &nbsp;&nbsp;Commercial paper | 1469 |  |  | 1469 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $198930 | $75 | $(286) | $198719 |

---

[**Table of Contents**](#TOC)

Available-for-sale securities in a loss position at September 30, 2025 and December 31, 2024 consist of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Continuous Loss Position**  | **Continuous Loss Position**  | **Continuous Loss Position**  | **Continuous Loss Position**  |
|  | **for Less than 12 Months** | **for Less than 12 Months** | **for 12 Months or More** | **for 12 Months or More** |
|  | <br>**Estimated**<br>**Fair Value** | **Gross**<br>**Unrealized**<br>**Losses** | <br>**Estimated**<br>**Fair Value** | **Gross**<br>**Unrealized**<br>**Losses** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **September 30, 2025** |  |  |  |  |
| U.S. treasuries | $14775 | $(2) | $— | $— |
| Government agency securities | 8981 | (23) | 1460 | (2) |
| Corporate debt | 20061 | (14) | 2636 | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $43817 | $(39) | $4096 | $(5) |
| **December 31, 2024** |  |  |  |  |
| U.S. treasuries | $26756 | $(21) | $— | $— |
| Government agency securities | 20062 | (90) |  |  |
| Corporate debt | 58967 | (175) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $105785 | $(286) | $— | $— |

---

The contractual maturities of securities classified as available-for-sale at September 30, 2025 were as follows:

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **September 30, 2025** |
|  | **Amortized**<br>**Cost** | **Estimated**<br>**Fair Value** |
|  | *(in thousands)* | *(in thousands)* |
| Due in one year or less | $132558 | $132638 |
| Due after one year through two years | 43483 | 43492 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $176041 | $176130 |

---

Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. There were no realized gains or losses, or unrealized losses from declines in fair value that are other than temporary, for the nine months ended September 30, 2025 and 2024.

*Accounts Receivable*

Accounts receivable is presented net of an allowance for doubtful accounts of $1.0 million at September 30, 2025 and December 31, 2024. The Company considers its current expectations of future economic conditions when estimating its allowance for doubtful accounts.

*Inventories*

Inventories at September 30, 2025 and December 31, 2024 consist of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
|  | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Materials | $139581 | $129178 |
| Work-in-process | 85965 | 88361 |
| Finished goods | 8697 | 3016 |
| Evaluation inventory | 29068 | 26180 |
| &nbsp;&nbsp;**Total** | $263311 | $246735 |

---

[**Table of Contents**](#TOC)

*Prepaid Expenses and Other Current Assets*

Prepaid expenses and other current assets primarily consist of supplier deposits, prepaid value-added tax, lease deposits, prepaid insurance, prepaid software and maintenance, and other receivables. The Company had deposits with its suppliers of $12.9 million and $18.7 million at September 30, 2025 and December 31, 2024, respectively.

*Property, Plant, and Equipment*

Property, plant, and equipment at September 30, 2025 and December 31, 2024 consist of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
|  | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Land | $5061 | $5061 |
| Building and improvements | 61604 | 61504 |
| Machinery and equipment <sup>(1)</sup> | 195829 | 190810 |
| Leasehold improvements | 55022 | 53759 |
| &nbsp;&nbsp;Gross property, plant, and equipment | 317516 | 311134 |
| Less: accumulated depreciation and amortization | 208396 | 197345 |
| &nbsp;&nbsp;**Property, plant, and equipment, net** | $109120 | $113789 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Machinery and equipment also includes software, furniture and fixtures

For the three and nine months ended September 30, 2025, depreciation expense was $4.1 million and $12.6 million, respectively and $4.5 million and $13.8 million, respectively, for the comparable 2024 period.

*Goodwill*

Goodwill represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and separately recognized. There were no changes to goodwill during the nine months ended September 30, 2025.

*Intangible Assets*

Intangible assets consist of purchased technology, customer relationships, patents, trademarks and tradenames, licenses, and backlog, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined.

The components of purchased intangible assets were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | <br>**Gross**<br>**Carrying**<br>**Amount** | **Accumulated**<br>**Amortization**<br>**and**<br>**Impairment** | <br>**Net** <br>**Amount** | <br>**Gross**<br>**Carrying**<br>**Amount** | **Accumulated**<br>**Amortization**<br>**and**<br>**Impairment** | <br>**Net**<br>**Amount** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| Technology | $355928 | $355156 | $772 | $355928 | $354066 | $1862 |
| Customer relationships | 146925 | 141279 | 5646 | 146925 | 139955 | 6970 |
| Trademarks and tradenames | 30910 | 30910 |  | 30910 | 30910 |  |
| Other | 3746 | 3746 |  | 3746 | 3746 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $537509 | $531091 | $6418 | $537509 | $528677 | $8832 |

---

Other intangible assets primarily consist of patents, licenses, and backlog.

[**Table of Contents**](#TOC)

**Note 4 — Liabilities**

*Accrued Expenses and Other Current Liabilities*

The components of accrued expenses and other current liabilities at September 30, 2025 and December 31, 2024 consist of:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
|  | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Payroll and related benefits | $22380 | $30398 |
| Warranty | 10034 | 9740 |
| Operating lease liabilities | 4059 | 3757 |
| Interest | 2332 | 1198 |
| Professional fees | 3571 | 1969 |
| Sales, use, and other taxes | 1396 | 1539 |
| Contingent consideration | 702 | 702 |
| Other | 5746 | 5892 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $50220 | $55195 |

---

*Warranty*

Warranties are typically valid for one year from the date of system final acceptance. The Company estimates the costs that may be incurred under the warranty which are determined by analyzing specific product and historical configuration statistics and regional warranty support costs and are affected by product failure rates, material usage, and labor costs incurred in correcting product failures during the warranty period. Unforeseen component failures or exceptional component performance can also result in changes to warranty costs. Changes in product warranty reserves for the nine months ended September 30, 2025 include:

---

| | |
|:---|:---|
|  | *(in thousands)* |
| **Balance - December 31, 2024** | $9740 |
| &nbsp;&nbsp;Warranties issued | 5337 |
| &nbsp;&nbsp;Consumption of reserves | (4488) |
| &nbsp;&nbsp;Changes in estimate | (555) |
| **Balance - September 30, 2025** | $10034 |

---

*Contract Liabilities and Performance Obligations*

Contract liabilities consist of unsatisfied performance obligations related to advanced payments received and billing in excess of revenue recognized. The contract liability balance as of December 31, 2024 was approximately $65.0 million, of which the Company recognized approximately $48.0 million in revenue during the nine months ended September 30, 2025.

This reduction in contract liabilities was offset in part by new billings for products and services which were unsatisfied performance obligations to customers and revenue had not yet been recognized as of September 30, 2025.

As of September 30, 2025, the Company has approximately $46.5 million of remaining performance obligations on contracts with an original estimated duration of one year or more, of which approximately 60% is expected to be recognized within one year, with the remaining amounts expected to be recognized between one to three years. The Company has elected to exclude disclosures regarding remaining performance obligations that have an original expected duration of one year or less.

[**Table of Contents**](#TOC)

*Convertible Senior Notes*

*2025 Notes*

On November 17, 2020, as part of the privately negotiated exchange agreement, the Company issued $132.5 million of 3.50% convertible senior notes due 2025 (the "2025 Notes"). The 2025 Notes bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, commencing on July 15, 2021. On May 19, 2023, in connection with the completion of a private offering of $230.0 million aggregate principal amount of 2.875% convertible senior notes due 2029 described below, the Company repurchased and retired approximately $106.0 million in aggregate principal amount of its outstanding 2025 Notes. The remaining principal amount of $26.5 million 2025 Notes matured on January 15, 2025 and were settled through the issuance of 1.1 million shares of the Company's common stock to the noteholders.

*2027 Notes*

On May 18, 2020, the Company completed a private offering of $125.0 million of 3.75% convertible senior notes due 2027 (the "2027 Notes"). The Company received net proceeds of approximately $121.9 million, after deducting underwriting discounts and fees and expenses payable by the Company. Additionally, the Company used approximately $10.3 million of cash to purchase capped calls, discussed below. The 2027 Notes bore interest at a rate of 3.75% per year, payable semiannually in arrears on June 1 and December 1 of each year, commencing on December 1, 2020. The 2027 Notes were scheduled to mature on June 1, 2027, unless earlier purchased by the Company, redeemed, or converted. On May 19, 2023, in connection with the completion of a private offering of $230.0 million aggregate principal amount of 2.875% convertible senior notes due 2029 described below, the Company repurchased and retired approximately $100.0 million in aggregate principal amount of its outstanding 2027 Notes. The remaining principal amount of $25.0 million 2027 Notes were settled on May 15, 2025 in a private transaction with all remaining 2027 Note holders for 1.6 million shares of the Company's common stock and $5.4 million in cash. The settlement was accounted for as an induced conversion resulting in an inducement expense of approximately $0.7 million for the nine months ended September 30, 2025, which is included within "Other income (expense), net" on the Consolidated Statement of Operations, and a decrease to additional paid-in capital of $20.2 million on the Consolidated Balance Sheets.

*2029 Notes*

On May 19, 2023, the Company completed a private offering of $230.0 million of 2.875% convertible senior notes due 2029 (the "2029 Notes"). The Company received net proceeds of approximately $223.2 million, after deducting underwriting discounts and fees and expenses payable by the Company. Additionally, the Company used approximately $198.8 million of net proceeds from the offering to fund the cash portion of the 2025 Notes and 2027 Notes extinguishments described above and the remainder for general corporate purposes. The 2029 Notes bear interest at a rate of 2.875% per year, payable semiannually in arrears on June 1 and December 1 of each year, commencing on December 1, 2023. The 2029 Notes mature on June 1, 2029, unless earlier purchased by the Company, redeemed, or converted. The Company will settle any conversions of the 2029 Notes by paying cash up to the aggregate principal amount of the 2029 Notes to be converted, and paying or delivering either cash, shares of Company's common stock, or a combination of cash and shares of common stock at the Company's election, in respect of the remainder, if any, of the conversion obligation in excess of the aggregate principal amount of the 2029 Notes being converted.

The 2029 Notes are unsecured senior obligations of Veeco and rank senior in right of payment to any of Veeco's subordinated indebtedness; equal in right of payment to all of Veeco's unsecured indebtedness that is not subordinated; effectively subordinated in right of payment to any of Veeco's secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally subordinated to all indebtedness and other liabilities (including trade payables) of Veeco's subsidiaries.

The Company may redeem for cash, at its option, all or any portion of the outstanding 2029 Notes at any time on or after June 8, 2026, at a redemption price equal to 100% of the principal amount of such 2029 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date, if the last reported sale price of the common stock has been at least 130% of the conversion price for the applicable series of 2029 Notes then in effect for at least 20 trading

[**Table of Contents**](#TOC)

days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides the redemption notice. Upon the Company's notice of redemption, holders may elect to convert their 2029 Notes based on the conversion rates and criteria outlined below.

The 2029 Notes are convertible at the option of the holders upon the satisfaction of specified conditions and during certain periods as described below. The initial conversion rate is 34.21852 shares of the Company's common stock per $1,000 principal amount, representing an initial effective conversion price of $29.22 per share of common stock. The conversion rate may be subject to adjustment upon the occurrence of certain specified events.

Holders may convert all or any portion of their 2029 Notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding February 1, 2029, only under the following circumstances:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) During any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) During the five consecutive business day period after any five consecutive trading day period (the "measurement period") in which the trading price per one thousand dollar principal amount of 2029 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Veeco's common stock and the conversion rate on each such trading day;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If the Company calls any or all of applicable series of the 2029 Notes for redemption at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Upon the occurrence of specified corporate events.

Holders may convert their 2029 Notes at any time, regardless of the foregoing circumstances, on February 1, 2029, until the close of business on the business day immediately preceding the maturity date.

The 2025, 2027, and 2029 Notes were recorded as a single unit within liabilities in the consolidated balance sheets as the conversion features within the Notes were not derivatives that require bifurcation and the Notes did not involve a substantial premium. Transaction costs of $1.9 million, $3.1 million, and $6.8 million incurred in connection with the issuance of the 2025 Notes, 2027 Notes, and 2029 Notes, respectively, were recorded as direct deductions from the related debt liabilities and recognized as non-cash interest expense using the effective interest method over the expected terms of the Notes.

The carrying value of the 2025 Notes, 2027 Notes, and 2029 Notes are as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Principal Amount** | **Unamortized transaction costs** | **Net carrying value** | **Principal Amount** | **Unamortized transaction costs** | **Net carrying value** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| 2025 Notes | $— | $— | $— | $26500 | $(4) | $26496 |
| 2027 Notes |  |  |  | 25000 | (223) | 24777 |
| 2029 Notes | 230000 | (4277) | 225723 | 230000 | (5075) | 224925 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net carrying value** | $230000 | $(4277) | $225723 | $281500 | $(5302) | $276198 |

---

[**Table of Contents**](#TOC)

Total interest expense related to the 2025 Notes, 2027 Notes, and 2029 Notes is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| Cash Interest Expense |  |  |  |  |
| &nbsp;&nbsp;Coupon interest expense - 2025 Notes | $— | $232 | $39 | $696 |
| &nbsp;&nbsp;Coupon interest expense - 2027 Notes |  | 234 | 347 | 702 |
| &nbsp;&nbsp;Coupon interest expense - 2029 Notes | 1653 | 1653 | 4959 | 4959 |
| Non-cash Interest Expense |  |  |  |  |
| &nbsp;&nbsp;Amortization of debt discount/transaction costs- 2025 Notes |  | 26 | 4 | 76 |
| &nbsp;&nbsp;Amortization of debt discount/transaction costs- 2027 Notes |  | 23 | 30 | 66 |
| &nbsp;&nbsp;Amortization of debt discount/transaction costs- 2029 Notes | 283 | 274 | 799 | 793 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Interest Expense** | $1936 | $2442 | $6178 | $7292 |

---

The Company determined the 2029 Notes are Level 2 liabilities in the fair value hierarchy and had an estimated fair value at September 30, 2025 of $290.7 million.

*Capped Call Transactions*

In connection with the offering of the 2027 Notes, on May 13, 2020, the Company entered into privately negotiated capped call transactions (the "Capped Call Transactions"), pursuant to capped call confirmations, covering the initial underlying shares of the 2027 Notes of approximately 8.9 million shares, for an aggregate premium of $10.3 million. The Capped Call Transactions feature a $13.98 exercise price and a capped price of approximately $18.46 per share, and mature on June 1, 2027. The Capped Call Transactions are subject to certain adjustments under the terms of the capped call confirmations.

The Capped Call Transactions are separate transactions entered into by the Company with the capped call counterparties, are not part of the terms of the 2027 Notes and did not change the previous holders' rights under the 2027 Notes. Previous holders of the 2027 Notes did not have any rights with respect to the Capped Call Transactions. The cost of the Capped Call Transactions is not expected to be tax-deductible as the Company did not elect to integrate the Capped Call Transactions into the 2027 Notes for tax purposes. The Company used a portion of the net proceeds from the offering of the 2027 Notes to pay for the Capped Call Transactions, and the cost of the Capped Call Transactions was recorded as a reduction of the Company's additional paid-in capital in the accompanying consolidated financial statements.

*Revolving Credit Facility* 

On December 16, 2021, the Company entered into a Loan and Security Agreement (the "Loan and Security Agreement") providing for a senior secured revolving credit facility in an aggregate principal amount of $150 million including a $15 million letter of credit sublimit. The Loan and Security Agreement was subsequently amended to increase the aggregate principal amount to $225 million on August 2, 2024 (the "Third Amendment"), and $250 million on June 16, 2025 (the "Fourth Amendment") (as amended to date, the "Credit Facility"). The Credit Facility matures on June 16, 2030, subject to a springing maturity date of March 2, 2029 upon the occurrence of certain liquidity events described in the Fourth Amendment. The Credit Facility is guaranteed by the Company's direct material U.S. subsidiaries, subject to customary exceptions. Borrowings under the Credit Facility are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary exceptions. Subject to certain conditions and the receipt of commitments from the lenders, the Loan and Security Agreement allows for revolving commitments under the Credit Facility to be increased by up to $100 million, with additional amounts available so long as the Secured Net Leverage Ratio (as defined in the Loan and Security Agreement) does not exceed 2.50 to 1.00. The existing lenders under the Credit Facility, are entitled, but not obligated, to provide such incremental commitments.

[**Table of Contents**](#TOC)

Borrowings will bear interest at a floating rate which can be, at the Company's option based on certain conditions in the Loan and Security Agreement, either (a) an alternate base rate plus an applicable rate ranging from 0.25% to 1.00% or (b) a Secured Overnight Financing Rate ("SOFR") (with a floor of 0.00%) for the specified interest period plus an applicable rate ranging from 1.25% to 2.00%, in each case, depending on the Company's Secured Net Leverage Ratio (as defined in the Loan and Security Agreement). The Company will pay an unused commitment fee ranging from 0.20% to 0.30% based on unused capacity under the Credit Facility and the Company's Secured Net Leverage Ratio. The Company may use the proceeds of borrowings under the Credit Facility to pay transaction fees and expenses, provide for its working capital needs and reimburse drawings under letters of credit and for other general corporate purposes.

The Loan and Security Agreement, contains customary affirmative covenants for transactions of this type, including, among others, the provision of financial and other information to the administrative agent, notice to the administrative agent upon the occurrence of certain material events, preservation of existence, maintenance of properties and insurance, compliance with laws, including environmental laws, the provision of additional guarantees, and an affiliate transactions covenant, subject to certain exceptions. The Loan and Security Agreement, contains customary negative covenants, including, among others, restrictions on the ability to merge and consolidate with other companies, incur indebtedness, refinance our existing convertible notes, grant liens or security interests on assets, make investments, acquisitions, loans, or advances, pay dividends, and sell or otherwise transfer assets.

The Loan and Security Agreement, contains financial maintenance covenants that require the Borrower to maintain an Interest Coverage Ratio (as defined in the Loan and Security Agreement) of not less than 3.00 to 1.00, a Total Net Leverage Ratio (as defined in the Loan and Security Agreement) of not more than 4.50 to 1.00, and a Secured Net Leverage Ratio (as defined in the Loan and Security Agreement) of not more than 3.00 to 1.00, in each case, tested at the end of each fiscal quarter. The Loan and Security Agreement, also provides for a number of customary events of default, including, among others: payment defaults to the lenders; voluntary and involuntary bankruptcy proceedings; covenant defaults; material inaccuracies of representations and warranties; certain change of control events; material money judgments; and other customary events of default. The occurrence of an event of default could result in the acceleration of obligations and the termination of lending commitments under the Loan and Security Agreement.

No amounts were outstanding under the Credit Facility as of September 30, 2025 or December 31, 2024.

*Other Liabilities*

Other Liabilities at September 30, 2025 and December 31, 2024 was approximately $3.8 million, which included medical and dental benefits for former executives, asset retirement obligations, contingent consideration, and tax liabilities.

**Note 5 — Commitments and Contingencies**

*Leases*

The Company's operating leases primarily include real estate leases for properties used for manufacturing, R&D activities, sales and service, and administration, as well as certain equipment leases. Some leases may include options to renew for a period of up to 5 years, while others may include options to terminate the lease. The weighted average remaining lease term of the Company's operating leases as of September 30, 2025 was 10 years, and the weighted average discount rate used in determining the present value of future lease payments was 5.7%.

[**Table of Contents**](#TOC)

The following table provides the maturities of lease liabilities at September 30, 2025:

---

| | |
|:---|:---|
|  | **Operating**<br>**Leases** |
|  | *(in thousands)* |
| **Payments due by period:** |  |
| 2025 | $859 |
| 2026 | 5119 |
| 2027 | 4868 |
| 2028 | 4439 |
| 2029 | 4302 |
| Thereafter | 30615 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total future minimum lease payments | 50202 |
| Less: Imputed interest | (13499) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $36703 |
| **Reported as of September 30, 2025** |  |
| Accrued expenses and other current liabilities | $4059 |
| Long-term operating lease liabilities | 32644 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $36703 |

---

Operating lease costs for the three and nine months ended September 30, 2025 were $1.2 million and $3.8 million, respectively, and $1.2 million and $3.6 million, respectively for the comparable 2024 period. Variable lease costs for the three and nine months ended September 30, 2025 were $0.3 million and $0.9 million, respectively and $0.3 million and $1.0 million, respectively for the comparable 2024 period. Additionally, the Company has an immaterial amount of short-term leases. Cash outflows from operating leases for the nine months ended September 30, 2025 and 2024 were $5.4 million and $5.0 million, respectively.

*Receivable Purchase Agreement*

The Company entered into a receivable purchase agreement with a financial institution to sell certain of its trade receivables from customers without recourse, up to $30.0 million at any point in time. Pursuant to this agreement, the Company sold no receivables for the three and nine months ended September 30, 2025, and $30.0 million was available under the agreement for additional sales of receivables as of September 30, 2025. The Company sold no receivables for the three months and $8.0 million for the nine months ended September 30, 2024. The net sale of accounts receivable under the agreement is reflected as a reduction of accounts receivable in the Company's Consolidated Balance Sheet at the time of sale and any fees for the sale of trade receivables were not material for the periods presented.

*Purchase Commitments*

Veeco has purchase commitments of $128.2 million at September 30, 2025 to secure the rights to various assets and services to be used in the future in the normal course of business, substantially all of which become due within one year.

*Bank Guarantees*

Veeco has bank guarantees and letters of credit issued by a financial institution on its behalf as needed. At September 30, 2025, outstanding bank guarantees and standby letters of credit totaled $7.6 million, and unused bank guarantees and letters of credit of $35.1 million were available to be drawn upon.

*Legal Proceedings*

The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.

[**Table of Contents**](#TOC)

**Note 6 — Equity**

*Statement of Stockholders' Equity*

The following tables present the changes in Stockholders' Equity:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | <br>**Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated** <br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income** | <br>**Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **Balance at December 31, 2024** | 56828 | $569 | $1227134 | $(458455) | $1522 | $770770 |
| Net income |  |  |  | 11947 |  | 11947 |
| Other comprehensive income (loss), net of tax |  |  |  |  | 108 | 108 |
| Share-based compensation expense |  |  | 9208 |  |  | 9208 |
| Settlement of the 2025 Notes | 1104 | 11 | 26489 |  |  | 26500 |
| Net issuance under employee stock plans | 360 | 3 | (6678) |  |  | (6675) |
| **Balance at March 31, 2025** | 58292 | $583 | $1256153 | $(446508) | $1630 | $811858 |
| Net income |  |  |  | 11733 |  | 11733 |
| Other comprehensive income (loss), net of tax |  |  |  |  | 30 | 30 |
| Share-based compensation expense |  |  | 9651 |  |  | 9651 |
| Settlement of the 2027 Notes | 1643 | 16 | 20215 |  |  | 20231 |
| Net issuance under employee stock plans | 226 | 3 | 2690 |  |  | 2693 |
| **Balance at June 30, 2025** | 60161 | $602 | $1288709 | $(434775) | $1660 | $856196 |
| Net income |  |  |  | 10596 |  | 10596 |
| Other comprehensive income (loss), net of tax |  |  |  |  | 144 | 144 |
| Share-based compensation expense |  |  | 9145 |  |  | 9145 |
| Net issuance under employee stock plans | (2) |  | (111) |  |  | (111) |
| **Balance at September 30, 2025** | 60159 | $602 | $1297743 | $(424179) | $1804 | $875970 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | <br>**Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated** <br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income** | <br>**Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **Balance at December 31, 2023** | 56364 | $564 | $1202440 | $(532169) | $1607 | $672442 |
| Net income |  |  |  | 21854 |  | 21854 |
| Other comprehensive income (loss), net of tax |  |  |  |  | (128) | (128) |
| Share-based compensation expense |  |  | 8082 |  |  | 8082 |
| Net issuance under employee stock plans | 273 | 2 | (14342) |  |  | (14340) |
| **Balance at March 31, 2024** | 56637 | $566 | $1196180 | $(510315) | $1479 | $687910 |
| Net income (loss) |  |  |  | 14944 |  | 14944 |
| Other comprehensive income (loss), net of tax |  |  |  |  | (12) | (12) |
| Share-based compensation expense |  |  | 9233 |  |  | 9233 |
| Net issuance under employee stock plans | 136 | 3 | 2935 |  |  | 2938 |
| **Balance at June 30, 2024** | 56773 | $569 | $1208348 | $(495371) | $1467 | $715013 |
| Net income |  |  |  | 21951 |  | 21951 |
| Other comprehensive income (loss), net of tax |  |  |  |  | 382 | 382 |
| Share-based compensation expense |  |  | 9459 |  |  | 9459 |
| Net issuance under employee stock plans | 5 | 1 | (287) |  |  | (286) |
| **Balance at September 30, 2024** | 56778 | $570 | $1217520 | $(473420) | $1849 | $746519 |

---

[**Table of Contents**](#TOC)

*Accumulated Other Comprehensive Income ("AOCI")*

The following table presents the changes in the balances of each component of AOCI, net of tax:

---

| | | | |
|:---|:---|:---|:---|
|  | <br><br>**Foreign**<br>**Currency**<br>**Translation** | **Unrealized**<br>**Gains (Losses)**<br>**on Available-**<br>**for-Sale** <br>**Securities** | <br>**Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **Balance - December 31, 2024** | $1777 | $(255) | $1522 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | 51 | 231 | 282 |
| **Balance - September 30, 2025** | $1828 | $(24) | $1804 |

---

There were immaterial reclassifications from AOCI into net income for the three and nine months ended September 30, 2025 and 2024.

**Note 7 — Share-based Compensation**

Restricted share awards are issued to employees and to members of our board of directors that are subject to specified restrictions and a risk of forfeiture. The restrictions typically lapse over one to four years and may entitle holders to dividends and voting rights. Other types of share-based compensation include performance share awards, performance share units, and restricted share units (collectively with restricted share awards, "restricted shares"), as well as options to purchase common stock.

Share-based compensation expense was recognized in the following line items in the Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| Cost of sales | $1771 | $1565 | $5105 | $4740 |
| Research and development | 2840 | 3111 | 8902 | 8422 |
| Selling, general, and administrative | 4534 | 4783 | 13997 | 13612 |
| &nbsp;&nbsp;**Total** | $9145 | $9459 | $28004 | $26774 |

---

For the nine months ended September 30, 2025, equity activity related to non-vested restricted shares and performance shares was as follows:

---

| | | |
|:---|:---|:---|
|  | <br>**Number of**<br>**Shares** | **Weighted**<br>**Average**<br>**Grant Date**<br>**Fair Value** |
|  | *(in thousands)* |  |
| **Balance - December 31, 2024** | 2604 | $32.53 |
| &nbsp;&nbsp;Granted | 1172 | 22.94 |
| &nbsp;&nbsp;Performance award adjustments | (21) | 45.28 |
| &nbsp;&nbsp;Vested | (898) | 31.63 |
| &nbsp;&nbsp;Forfeited | (102) | 26.73 |
| **Balance - September 30, 2025** | 2755 | $28.86 |

---

**Note 8 — Income Taxes**

Income taxes are estimated for each of the jurisdictions in which the Company operates. Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting

[**Table of Contents**](#TOC)

purposes and the amounts used for income tax purposes, as well as the tax effect of carryforwards. Realization of net deferred tax assets is dependent on future taxable income.

At the end of each interim reporting period, the effective tax rate is aligned with expectations for the full year. This estimate is used to determine the income tax provision on a year-to-date basis and may change in subsequent interim periods.

Income before income taxes and income tax expense for the three and nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Income before income taxes | $| 11875 | $| 24658 | $| 39481 | $| 64479 |
| Income tax expense | $ | 1279 | $ | 2707 | $| 5205 | $| 5730 |
| Effective tax rate |  | 10.77% |  | 10.98% |  | 13.18% |  | 8.89% |

---

The Company's income tax expense for the three and nine months ended September 30, 2025 was $1.3 million and $5.2 million, respectively, compared to $2.7 million and $5.7 million, respectively, for the comparable prior period.

For the three and nine months ended September 30, 2025, the effective tax rate was favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. Additionally, the effective tax rate was also impacted by a discrete income tax expense resulting from the share-based compensation shortfall. For the three and nine months ended September 30, 2024, the effective tax rate was favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. Additionally, the effective tax rate was lower than the U.S. statutory tax rate primarily relating to a discrete income tax benefit for share-based compensation windfall.

The One Big Beautiful Bill Act ("OBBBA") was enacted on July 4, 2025, which contains a broad range of tax law changes affecting businesses. The provisions of the OBBBA have different effective dates where some are effective in 2025 and others not until 2026. The Company continues to evaluate the full effects of the legislation. Based on our analysis, these impacts have not had a material effect on Company's financial position, results of operations or cash flow in the current fiscal year. The provisions effective in 2025 have been reflected in the Company's consolidated operating results for the three and nine months ended September 30, 2025.

**Note 9 — Segment Reporting and Geographic Information**

The Company operates and measures its results in one operating segment and therefore has one reportable segment: the development, manufacture, sales, and support of semiconductor and thin film process equipment primarily sold to make electronic devices. The accounting policies of this one operating segment are the same as those described in the Company's 2024 Form 10-K. The Chief Operating Decision Maker ("CODM"), the Chief Executive Officer, assesses segment performance and decides how to allocate resources based on net income that is reported on the Consolidated Statements of Operations. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets. The Company does not have intra-entity sales or transfers. The CODM uses net income to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the segment or into other parts of the Company, such as for acquisitions. Net income is used to monitor forecast versus actual results. The CODM also uses net income in competitive analysis by benchmarking the Company's competitors. The competitive analysis along with the monitoring of forecasted versus actual results are used in assessing performance of the segment. The Company regularly provides management reports to the CODM on a consolidated expense basis which includes actuals, forecasted, and budgeted information. These reports are similar to the Company's consolidated financial statements.

[**Table of Contents**](#TOC)

There are no additional expenses categories and amounts that meet the definition of significant expense items that are regularly provided to the CODM and included in the reported measure of net income.

Veeco serves the following four end-markets:

*Semiconductor*

The Semiconductor market refers to early process steps in logic and memory applications where silicon wafers are processed. There are many different process steps in forming patterned wafers, such as deposition, etching, masking, and doping, where the microchips are created but remain on the silicon wafer. This market includes mask blank production for extreme ultraviolet ("EUV") lithography, as well as Advanced Packaging, which refers to a portfolio of wafer-level assembly technologies that enable improved performance of electronic products, such as smartphones, high-end servers, and graphical processors.

*Compound Semiconductor*

The Compound Semiconductor market includes Photonics, Power Electronics, RF Filters and Amplifiers, and Solar applications. Photonics refers to light source technologies and laser-based solutions for 3D sensing, datacom and telecom applications. This includes micro-LED, laser diodes, edge emitting lasers and vertical cavity surface emitting lasers ("VCSELs"). Power Electronics refers to semiconductor devices such as rectifiers, inverters and converters for the control and conversion of electric power in applications such as fast or wireless charging of consumer electronics and automotive applications. RF power amplifiers and filters (including surface acoustic wave ("SAW") and bulk acoustic wave ("BAW") filters) are used in 5G communications infrastructure, smartphones, tablets, and mobile devices. They make use of radio waves for wireless broadcasting and/or communications. Solar refers to power obtained by harnessing the energy of the sun through the use of compound semiconductor devices such as photovoltaics.

*Data Storage* 

Data Storage refers to the Hard Disk Drive ("HDD") market, for which our systems enable customers to manufacture thin film magnetic heads for hard disk drives as part of large capacity storage applications.

*Scientific & Other*

Scientific & Other refers to advanced materials research and a range of manufacturing applications including optical coatings (laser mirrors, optical filters, and anti-reflective coatings).

[**Table of Contents**](#TOC)

Sales by end-market and geographic region for the three and nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **Sales by end-market** |  |  |  |  |
| &nbsp;&nbsp;Semiconductor | $118322 | $124143 | $366019 | $354463 |
| &nbsp;&nbsp;Compound Semiconductor | 10912 | 15556 | 39506 | 54781 |
| &nbsp;&nbsp;Data Storage | 9971 | 32750 | 29030 | 84727 |
| &nbsp;&nbsp;Scientific & Other | 26676 | 12358 | 64722 | 41199 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $165881 | $184807 | $499277 | $535170 |
| **Sales by geographic region** |  |  |  |  |
| &nbsp;&nbsp;United States | $26513 | $59207 | $72427 | $129819 |
| &nbsp;&nbsp;EMEA<sup>(1)</sup> | 11581 | 9898 | 42451 | 42188 |
| &nbsp;&nbsp;China | 45650 | 54590 | 144032 | 184274 |
| &nbsp;&nbsp;Rest of APAC | 82100 | 60969 | 240262 | 178124 |
| &nbsp;&nbsp;Rest of World | 37 | 143 | 105 | 765 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $165881 | $184807 | $499277 | $535170 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) EMEA consists of Europe, the Middle East, and Africa

For geographic reporting, sales are attributed to the location in which the customer facility is located.

**Note 10 — Subsequent Events**

*Merger Agreement with Axcelis Technologies, Inc.*

On September 30, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Axcelis Technologies, Inc. a Delaware corporation ("Axcelis"), and Victory Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Axcelis ("Merger Sub"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub will merge with and into Veeco (the "Merger"), with Veeco surviving as a wholly-owned subsidiary of Axcelis. The Merger Agreement was unanimously approved by Veeco's board of directors (except for one (1) independent director who serves on the Axcelis board of directors as well and thus recused himself) and is subject to certain customary closing conditions, including the approval by the stockholders of each company and various regulatory approvals. Subject to the satisfaction or (to the extent permissible) waiver of such conditions, the Merger is currently expected to close in the second half of 2026.

Under the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company common stock issued and outstanding immediately prior to the Effective Time (other than shares owned by Axcelis, the Company, Merger Sub, or their wholly-owned subsidiaries) will be converted into the right to receive 0.3575 newly issued shares of Axcelis common stock (the "Axcelis Common Stock"). No fractional shares of Axcelis will be issued in the Merger, and the Company stockholders will receive cash in lieu of fractional shares as part of the merger consideration. Following the Merger, Axcelis' common stockholders are expected to own approximately 58.4% of the shares of Axcelis Common Stock on a fully diluted basis, and the Company's common stockholders will own approximately 41.6%.

The Merger Agreement contains customary representations, warranties, and covenants, including restrictions on the conduct of business prior to closing and provisions regarding the treatment of the Company's outstanding equity awards and employee benefits. The Merger Agreement may be terminated under certain circumstances, including by mutual consent of the Company and Axcelis or if the Merger is not consummated by September 30, 2026 (subject to automatic extensions until as late as June 30, 2027 under certain conditions with respect to the receipt of regulatory approvals).

If the board of directors of either party makes an Adverse Recommendation Change, as defined in the Merger Agreement, the other party shall have the right to terminate the Merger Agreement, and the non-terminating party will be

[**Table of Contents**](#TOC)

required to pay the other party the following termination fee: (i) if the non-terminating party is Axcelis, a termination fee of $108,700,000; and (ii) if the non-terminating party is Veeco, a termination fee of $77,500,000. Each party may also be required to pay such termination fee if such party enters into a competing proposal within twelve months of termination of the Merger Agreement under certain circumstances. In addition, if the Merger Agreement is terminated by a party as a result of the other party's failure to obtain stockholder approval, or is terminated by a party due to the other party's breach of the Merger Agreement that would result in a failure of an applicable closing condition (subject to the applicable cure period set forth in the Merger Agreement), then the non-terminating party will be required to pay a fixed expense reimbursement amount of $15,000,000.

The Company incurred approximately $2.6 million in legal, accounting, consulting fees and employee-related costs in connection with the proposed Merger during the three and nine months ended September 30, 2025, included as part of Selling, General, and Administrative expenses on the Consolidated Statement of Operations.

Additional information regarding the Merger Agreement and the proposed Merger is included in the Company's Current Report on Form 8-K filed with the SEC on October 1, 2025.

*Fifth Amendment to Loan and Security Agreement*

On September 30, 2025, the Company entered into a Fifth Amendment (the "Fifth Amendment") to the Loan and Security Agreement referenced in Note 4 above. The Fifth Amendment makes certain amendments to the definition of "Change of Control" and the "Merger, Consolidation and Sale of Assets" covenant in the Loan and Security Agreement.

[**Table of Contents**](#TOC)

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Cautionary Statement Regarding Forward Looking Statements**

Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to facilitate an understanding of our business and results of operations. This MD&A should be read in conjunction with our Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements included elsewhere in this Form 10-Q. The following discussion contains forward-looking statements and should also be read in conjunction with the cautionary statement set forth at the beginning of this Form 10-Q.

The following section generally discusses 2025 and 2024 items and year-to-year comparisons between 2025 and 2024. Discussions of 2024 items that are not included in this Form 10-Q can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2 of our Quarterly Report on Form 10-Q for the interim period ended September 30, 2024, filed on November 6, 2024.

**Executive Summary**

We are an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, and single wafer wet processing technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco's systems and service offerings, visit www.veeco.com.

**Merger with Axcelis Technologies, Inc.**

On September 30, 2025, we entered into an Agreement and Plan of Merger (the "Merger Agreement") with Axcelis Technologies, Inc., a Delaware corporation ("Axcelis"), and Victory Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Axcelis ("Merger Sub"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub shall be merged with and into Veeco (the "Merger"), with Veeco surviving as a wholly-owned subsidiary of Axcelis. The Merger Agreement was unanimously approved by our board of directors (except for one (1) independent director who serves on the Axcelis board of directors as well and thus recused himself) and is subject to certain customary closing conditions, including the approval by the stockholders of each company and various regulatory approvals. For more information regarding the previously announced Merger, see Note 10 *Subsequent Events* to the accompanying Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

**Business Update**

Sales in the Semiconductor industry are estimated to have increased year-over-year in 2024 to around $650 billion. Looking ahead, industry analysts are forecasting long-term growth of the industry, driven by secular growth trends such as artificial intelligence, high-performance computing, mobile connectivity, and the electrification of the automotive industry. Additionally, government investments in the Semiconductor industry are projected to accelerate global spending in next-generation technologies.

Growth in the Semiconductor industry, coupled with increasing technological complexity of Semiconductor chips, are expected to drive long-term growth in WFE spending. In an effort to improve chip performance, optimize power consumption, and reduce costs, today's most advanced Semiconductor manufacturers are shrinking device geometries, investing in more complex transistor designs such as Gate-All-Around and exploring 3D architectures. As a result, growth of the WFE market is forecasted to keep pace with long-term growth of the Semiconductor industry, which we believe should benefit semiconductor capital equipment providers, including Veeco.

Our strategy of investing in advanced logic and memory has enabled our Semiconductor business to outperform WFE growth for four consecutive years. Veeco's technologies are at the forefront of enabling new technical innovations in the

[**Table of Contents**](#TOC)

manufacture of high-performance AI chips and High-Bandwidth Memory ("HBM"). We continue to invest in new technologies to expand our SAM to a broad range of new applications.

While the long-term outlook of the Semiconductor industry remains favorable, recently enacted tariffs, foreign and domestic, have resulted in uncertainty across Veeco's business. The tariffs have resulted in an increase in certain of our costs and those of our customers and could impact future end market demand. Given the dynamic nature of the situation, we continue to evaluate the potential impacts to our business, and our team is working diligently with our suppliers and customers to assess, manage and mitigate the related impacts.

Semiconductor revenue decreased by 5% in the third quarter from the comparable prior year period, comprising 71% of total revenue. Revenue was primarily driven by system shipments of our Laser Spike Annealing ("LSA"), Ion Beam Deposition EUV for mask blanks and our Advanced Packaging wet processing.

Our laser annealing solutions continue to gain traction at advanced logic nodes, highlighted by recent order activity and shipments to leading-edge logic customers Gate-All-Around nodes. In the memory market, we continue to ship LSA systems to a Tier 1 customer for high volume production of HBM and advanced DRAM devices.

We have two next generation laser annealing systems under evaluation at Tier 1 foundry and logic customers. This next generation system, the NSA500, covers the nano-second annealing regime and complements our LSA product. This new system is part of our continued effort to enable our customers' product roadmap by providing annealing solutions and driving higher device performance. Nanosecond annealing provides Veeco with an opportunity to expand our laser annealing SAM for new advanced node logic and memory applications, including low thermal budget anneals for Gate-All-Around transistors and advanced 3D devices.

The ongoing adoption of EUV Lithography for advanced node semiconductor manufacturing continues to drive demand for our Ion Beam Deposition EUV system for mask blanks. Leading logic and memory customers expect EUV and High Numerical Aperture ("High-NA") lithography to be integral to their future roadmaps, which our Ion Beam Deposition technology is a key enabler of the EUV mask blank Multiple Layer Mirror. Our product roadmap is well positioned as the industry adopts next-generation High-NA EUV lithography, and we are expanding our EUV related business to EUV pellicles which are increasingly being used to improve the productivity of EUV steps. Our IBD-EUV system is used to form the high-transparency membrane used in pellicles.

We also have two Ion Beam Deposition "IBD300" systems under evaluation at leading DRAM memory customers. Our IBD300 system provides Veeco with another opportunity to expand our SAM to advanced node applications where low resistance films are critical. These initial systems are being evaluated for advanced memory applications, such as DRAM bitline.

In Advanced Packaging, our Wet Processing systems are used for several applications, and we continue to see strong demand driven by Heterogenous Integration and 3D Packaging for AI and high-performance computing. In the third quarter of 2025, we had increased order activity supporting these end markets.

Our Advanced Packaging lithography systems are used for packaging applications such as 2.5D and 3D packaging, fan out wafer level packaging and other advanced packaging solutions. We are seeing an uptick in the order activity from several OSAT customers driven by AI and consumer markets recovery.

Looking ahead, we anticipate seeing growth in the semiconductor market in leading-edge investment driven by new nodes and AI-related demand, including investment in Gate-All-Around nodes, High-Bandwidth Memory, and 3D packaging for AI.

Veeco also serves customers in the Compound Semiconductor, Data Storage, and Scientific & Other markets. We address the Compound Semiconductor market with a broad portfolio of technologies, including Wet Processing, MOCVD, MBE and Ion Beam, for Power Electronics, Photonics, and 5G RF applications. Sales in the Compound Semiconductor market declined in the third quarter from the comparable prior year period. In GaN Power, emerging use cases have driven some traditional silicon power electronics manufacturers to consider adoption of GaN at 300mm.

[**Table of Contents**](#TOC)

Additionally, we received an order for a Propel 300mm GaN on Silicon Epitaxy system from a leading power device IDM customer. This order cements our position as a leader in 300mm MOCVD technology.

We are also seeing photonics orders driven by demand for space-grade solar cells and panels, optical communication solutions for datacom industry, as well as opportunities in MicroLEDs for applications such as luxury TVs, AR/VR, and automotive.

We address the Data Storage market with sales of our Ion Beam technology. Demand for our Ion Beam products is driven by demand for cloud and AI Data Centers. Revenue in our Data Storage market declined in the third quarter from the comparable prior year period. While customers are not adding new system capacity in 2025, we have started seeing new order activity in the third quarter, driven by increased customer utilization rates and adoption of new technologies like Heat Assisted-Magnetic-Recording ("HAMR").

Sales in the Scientific & Other market are largely driven by sales to government-funded laboratories, universities, and research institutions. We address the Scientific & Other market with several technologies, including MBE, ALD, MOCVD, Wet Processing, and IBD/IBE, which support diverse R&D and niche low-volume production applications. Sales in this market increased in the third quarter from the comparable prior year period driven by optical deposition systems.

**Results of Operations**

**For the three months ended September 30, 2025 and 2024**

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the indicated periods in 2025 and 2024 and the period-over-period dollar and percentage changes for those line items. Our results of operations are reported as one business segment, represented by our single operating segment.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Change** | **Change** |
|  | **2025** | **2025** | **2024** | **2024** | **Period to Period** | **Period to Period** |
|  | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* |
| Net sales | $165881 | 100% | $184807 | 100% | $(18926) | (10)% |
| Cost of sales | 98178 | 59% | 105596 | 57% | (7418) | (7)% |
| Gross profit | 67703 | 41% | 79211 | 43% | (11508) | (15)% |
| Operating expenses, net: |  |  |  |  |  |  |
| &nbsp;&nbsp;Research and development | 28988 | 17% | 32216 | 17% | (3228) | (10)% |
| &nbsp;&nbsp;Selling, general, and administrative | 27263 | 16% | 25291 | 14% | 1972 | 8% |
| &nbsp;&nbsp;Amortization of intangible assets | 771 | 0% | 1687 | 1% | (916) | (54)% |
| &nbsp;&nbsp;Other operating expense (income), net | 127 | 0% | (4318) | (2)% | 4445 | (103)% |
| Total operating expenses, net | 57149 | 34% | 54876 | 30% | 2273 | 4% |
| Operating income | 10554 | 6% | 24335 | 13% | (13781) | (57)% |
| &nbsp;&nbsp;Interest income, net | 1321 | 1% | 323 | 0% | 998 | 309% |
| Income before income taxes | 11875 | 7% | 24658 | 13% | (12783) | (52)% |
| &nbsp;&nbsp;Income tax expense | 1279 | 1% | 2707 | 1% | (1428) | (53)% |
| Net income | $10596 | 6% | $21951 | 12% | $(11355) | (52)% |

---

[**Table of Contents**](#TOC)

*Net Sales*

The following is an analysis of sales by market and by region:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Change** | **Change** |
|  | **2025** | **2025** | **2024** | **2024** | **Period to Period** | **Period to Period** |
|  | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* |
| **Sales by end-market** |  |  |  |  |  |  |
| &nbsp;&nbsp;Semiconductor | $118322 | 71% | $124143 | 67% | $(5821) | (5)% |
| &nbsp;&nbsp;Compound Semiconductor | 10912 | 7% | 15556 | 8% | (4644) | (30)% |
| &nbsp;&nbsp;Data Storage | 9971 | 6% | 32750 | 18% | (22779) | (70)% |
| &nbsp;&nbsp;Scientific & Other | 26676 | 16% | 12358 | 7% | 14318 | 116% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $165881 | 100% | $184807 | 100% | $(18926) | (10)% |
| **Sales by geographic region** |  |  |  |  |  |  |
| &nbsp;&nbsp;United States | $26513 | 16% | $59207 | 32% | $(32694) | (55)% |
| &nbsp;&nbsp;EMEA | 11581 | 7% | 9898 | 5% | 1683 | 17% |
| &nbsp;&nbsp;China | 45650 | 28% | 54590 | 30% | (8940) | (16)% |
| &nbsp;&nbsp;Rest of APAC | 82100 | 49% | 60969 | 33% | 21131 | 35% |
| &nbsp;&nbsp;Rest of World | 37 | - | 143 | - | (106) | (74)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $165881 | 100% | $184807 | 100% | $(18926) | (10)% |

---

Sales decreased for the three months ended September 30, 2025 against the comparable prior year period driven by a decrease in sales in the Data Storage, Semiconductor, and Compound Semiconductor markets, partially offset by an increase in sales in the Scientific & Other market. By geography, sales decreased in the United States and China, partially offset by increased sales in the Rest of APAC and EMEA regions. Sales in the Rest of APAC region for the three months ended September 30, 2025 included sales in Taiwan and Japan of $54.9 million and $10.3 million, respectively. Sales in the Rest of APAC region for the three months ended September 30, 2024 included sales in Taiwan and Japan of $49.9 million, and $4.0 million respectively. In light of the global nature of our business, we are impacted by conditions in the various countries in which we and our customers operate, including the recent tariff and trade dynamics. We expect there will continue to be year-to-year variations in our future sales distribution across markets and geographies.

*Gross Profit*

For the three months ended September 30, 2025, gross profit decreased against the comparable prior period primarily due to a decrease in sales volume, as well as a decrease in gross margins. Gross margins decreased principally due to lower volume and higher logistics costs partially offset by favorable product mix. Additionally other factors will cause our gross margins to fluctuate each period. We expect higher costs in future periods as we incur tariffs on imported materials from overseas suppliers, as well as higher costs from domestic suppliers incurring tariffs on their imports. Additionally, we anticipate a reduction in gross margin for the remainder of the year primarily driven by a shift in product mix.

*Research and Development*

The markets we serve are characterized by continuous technological development and product innovation, and we invest in various research and development initiatives to maintain our competitive advantage and achieve our growth objectives. Research and development expenses decreased for the three months ended September 30, 2025 against the comparable prior period due to a decrease in personnel-related and operating-related expenses as part of our efforts to manage costs.

[**Table of Contents**](#TOC)

*Selling, General, and Administrative*

Selling, general, and administrative expenses increased for the three months ended September 30, 2025 against the comparable prior period due to expenses incurred associated with the Company entering into the Merger Agreement described above, partially offset by a reduction in personnel-related expenses as part of our efforts to manage costs.

*Amortization Expense*

Amortization expense decreased compared to the comparable prior year period primarily due to changes in amortization expense to reflect expected cash flows of certain intangible assets, and certain other intangible assets becoming fully amortized, as well as the full impairment of the Epiluvac related intangibles in 2024.

*Other Operating Expense (Income), Net* 

Other operating income decreased compared to the comparable prior year period primarily due to reduction in the expected earn-out payment to the previous shareholders of Epiluvac during the three months ended September 30, 2024.

*Interest Income (Expense)*

We recorded net interest income of $1.3 million for the three months ended September 30, 2025, compared to net interest income of $0.3 million for the comparable prior year period. The increase in net interest income was primarily due to reduced interest expense on the 2025 Notes as they matured on January 15, 2025 and the 2027 Notes that were settled on May 15, 2025.

*Income Taxes*

Our tax expense for the three months ended September 30, 2025, was $1.3 million, compared to $2.7 million of tax expense for the comparable prior period. For the three months ended September 30, 2025, the effective tax rate was lower than the U.S. statutory tax rate primarily relating to tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. For the three months ended September 30, 2024, the effective tax rate was lower than the U.S. statutory tax rate primarily relating to tax benefits related to Foreign-Derived Intangible Income and research and development tax credits.

[**Table of Contents**](#TOC)

**For the nine months ended September 30, 2025 and 2024**

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the indicated periods in 2025 and 2024 and the period-over-period dollar and percentage changes for those line items. Our results of operations are reported as one business segment, represented by our single operating segment.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Change** | **Change** |
|  | **2025** | **2025** | **2024** | **2024** | **Period to Period** | **Period to Period** |
|  | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* |
| Net sales | $499277 | 100% | $535170 | 100% | $(35893) | (7)% |
| Cost of sales | 294380 | 59% | 305150 | 57% | (10770) | (4)% |
| Gross profit | 204897 | 41% | 230020 | 43% | (25123) | (11)% |
| Operating expenses, net: |  |  |  |  |  |  |
| &nbsp;&nbsp;Research and development | 89062 | 18% | 93554 | 17% | (4492) | (5)% |
| &nbsp;&nbsp;Selling, general, and administrative | 76218 | 15% | 74586 | 14% | 1632 | 2% |
| &nbsp;&nbsp;Amortization of intangible assets | 2413 | 0% | 5403 | 1% | (2990) | (55)% |
| &nbsp;&nbsp;Other operating expense (income), net | 132 | 0% | (6625) | (1)% | 6757 | \* |
| Total operating expenses, net | 167825 | 34% | 166918 | 31% | 907 | 1% |
| Operating income (loss) | 37072 | 7% | 63102 | 12% | (26030) | (41)% |
| &nbsp;&nbsp;Interest income (expense), net | 3062 | 1% | 1377 | 0% | 1685 | 122% |
| &nbsp;&nbsp;Other income (expense), net | (653) | (0)% |  | 0% | (653) | \* |
| Income (loss) before income taxes | 39481 | 8% | 64479 | 12% | (24998) | (39)% |
| &nbsp;&nbsp;Income tax expense (benefit) | 5205 | 1% | 5730 | 1% | (525) | (9)% |
| Net income (loss) | $34276 | 7% | $58749 | 11% | $(24473) | (42)% |

---

\* Not meaningful

*Net Sales*

The following is an analysis of sales by market and by region:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Change** | **Change** |
|  | **2025** | **2025** | **2024** | **2024** | **Period to Period** | **Period to Period** |
|  | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* |
| **Sales by end-market** |  |  |  |  |  |  |
| &nbsp;&nbsp;Semiconductor | $366019 | 73% | $354463 | 66% | $11556 | 3% |
| &nbsp;&nbsp;Compound Semiconductor | 39506 | 8% | 54781 | 10% | (15275) | (28)% |
| &nbsp;&nbsp;Data Storage | 29030 | 6% | 84727 | 16% | (55697) | (66)% |
| &nbsp;&nbsp;Scientific & Other | 64722 | 13% | 41199 | 8% | 23523 | 57% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $499277 | 100% | $535170 | 100% | $(35893) | (7)% |
| **Sales by geographic region** |  |  |  |  |  |  |
| &nbsp;&nbsp;United States | $72427 | 15% | $129819 | 24% | $(57392) | (44)% |
| &nbsp;&nbsp;EMEA | 42451 | 9% | 42188 | 8% | 263 | 1% |
| &nbsp;&nbsp;China | 144032 | 29% | 184274 | 35% | (40242) | (22)% |
| &nbsp;&nbsp;Rest of APAC | 240262 | 48% | 178124 | 33% | 62138 | 35% |
| &nbsp;&nbsp;Rest of World | 105 | - | 765 | - | (660) | (86)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $499277 | 100% | $535170 | 100% | $(35893) | (7)% |

---

Sales decreased for the nine months ended September 30, 2025 against the comparable prior year period driven by a decrease in sales in the Data Storage and Compound Semiconductor markets, partially offset by an increase in sales in the Semiconductor and Scientific & Other markets. By geography, sales decreased in the United States, China, and the Rest of the World partially offset by increased sales in the Rest of APAC and EMEA regions. Sales in the Rest of APAC

[**Table of Contents**](#TOC)

region for the nine months ended September 30, 2025 included sales in Taiwan, Japan, and Singapore of $132.9 million, $39.0 million, and $33.1 million, respectively. Sales in the Rest of APAC region for the nine months ended September 30, 2024 included sales in Taiwan and Japan of $90.2 million, and $45.8 million respectively. In light of the global nature of our business, we are impacted by conditions in the various countries in which we and our customers operate, including the recent tariff and trade dynamics. We expect there will continue to be year-to-year variations in our future sales distribution across markets and geographies.

*Gross Profit*

For the nine months ended September 30, 2025, gross profit decreased against the comparable prior period primarily due to a decrease in sales volume, as well as a decrease in gross margins. Gross margins decreased principally due to lower volume and higher logistics costs. Additionally other factors will cause our gross margins to fluctuate each period. We expect higher costs in future periods as we incur tariffs on imported materials from overseas suppliers, as well as higher costs from domestic suppliers incurring tariffs on their imports.

*Research and Development*

The markets we serve are characterized by continuous technological development and product innovation, and we invest in various research and development initiatives to maintain our competitive advantage and achieve our growth objectives. Research and development expenses decreased for the nine months ended September 30, 2025 against the comparable prior period due to a decrease in personnel-related and operating-related expenses as part of our efforts to manage costs.

*Selling, General, and Administrative*

Selling, general, and administrative expenses increased for the nine months ended September 30, 2025 against the comparable prior period due to expenses incurred associated with the Company entering into the Merger Agreement described above, partially offset by a reduction in personnel-related expenses as part of our efforts to manage costs.

*Amortization Expense*

Amortization expense decreased compared to the comparable prior year period primarily due to changes in amortization expense to reflect expected cash flows of certain intangible assets, and certain other intangible assets becoming fully amortized, as well as the full impairment of the Epiluvac related intangibles in 2024.

*Other Operating Expense (Income), Net* 

Other operating income decreased compared to the comparable prior year period primarily due to a reduction in the expected earn-out payment to the previous shareholders of Epiluvac, as well as proceeds from the sale of productive assets during the nine months ended September 30, 2024.

*Interest Income (Expense)*

We recorded net interest income of $3.1 million for the nine months ended September 30, 2025, compared to net interest income of $1.3 million for the comparable prior year period. The increase in net interest income was primarily due to reduced interest expense on the 2025 Notes as they matured on January 15, 2025 and the 2027 Notes that were settled on May 15, 2025.

*Income Taxes*

Our tax expense for the nine months ended September 30, 2025, was $5.2 million, compared to $5.7 million of tax expense for the comparable prior period. For the nine months ended September 30, 2025, the effective tax rate was favorably impacted by tax benefits related to Foreign-Derived Intangible Income and research and development tax credits, partially offset by a discrete income tax expense resulting from the share-based compensation shortfall. For the

[**Table of Contents**](#TOC)

nine months ended September 30, 2024, the effective tax rate was favorably impacted by tax benefits related to Foreign-Derived Intangible Income and research and development tax credits, as well as a discrete income tax benefit resulting from the share-based compensation windfall.

**Liquidity and Capital Resources**

Our cash and cash equivalents, restricted cash, and short-term investments are as follows:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
|  | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Cash and cash equivalents | $193192 | $145595 |
| Restricted cash | 30 | 224 |
| Short-term investments | 176130 | 198719 |
| &nbsp;&nbsp;**Total** | $369352 | $344538 |

---

At September 30, 2025 and December 31, 2024, cash and cash equivalents of $36.4 million and $45.1 million, respectively, were held outside the United States. As of September 30, 2025, we had $23.8 million of accumulated undistributed earnings generated by our non-U.S. subsidiaries for which the U.S. tax has previously been provided. Approximately $9.8 million of undistributed earnings will be subject to foreign withholding taxes if distributed back to the United States and we accrued $1.0 million for foreign withholding taxes for the undistributed earnings.

We believe that our projected cash flow from operations, combined with our cash and short-term investments, will be sufficient to meet our projected working capital requirements, contractual obligations, and other cash flow needs for the next twelve months, including scheduled principal and interest payments on our convertible senior notes, purchase commitments, and payments required under our operating leases.

A summary of the cash flow activity for the nine months ended September 30, 2025 and 2024 is as follows:

*Cash Flows from Operating Activities*

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Net income | $34276 | $58749 |
| Non-cash items: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 15038 | 19161 |
| &nbsp;&nbsp;Non-cash interest expense | 833 | 935 |
| &nbsp;&nbsp;Deferred income taxes | 427 | 1885 |
| &nbsp;&nbsp;Share-based compensation expense | 28004 | 26774 |
| &nbsp;&nbsp;Change in contingent consideration |  | (4775) |
| Changes in operating assets and liabilities | (34011) | (67299) |
| &nbsp;&nbsp;**Net cash provided by (used in) operating activities** | $44567 | $35430 |

---

Net cash provided by operating activities was $44.6 million for the nine months ended September 30, 2025 and was due to net income of $34.3 million and adjustments for non-cash items of $44.3 million, partially offset by a decrease in cash flow from changes in operating assets and liabilities of $34.0 million. The changes in operating assets and liabilities were largely attributable to a decrease in contract liabilities and increases in accounts receivables, and inventories, partially offset by a decrease in prepaid expenses and other current assets.

[**Table of Contents**](#TOC)

*Cash Flows from Investing Activities*

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Capital expenditures | $(12928) | $(12934) |
| Changes in investments, net | 24860 | (7929) |
| Proceeds from the sale of productive assets |  | 2033 |
| &nbsp;&nbsp;**Net cash provided by (used in) investing activities** | $11932 | $(18830) |

---

The cash provided by investing activities during the nine months ended September 30, 2025 was primarily attributable to net cash provided for investment activity, partially offset by capital expenditures. The cash provided by investing activities during the nine months ended September 30, 2024 was primarily attributable to net cash used for capital expenditures, and net investment activity, partially offset by proceeds from the sale of productive assets.

*Cash Flows from Financing Activities*

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Settlement of equity awards, net of withholding taxes | $(3048) | $(10507) |
| Debt issuance costs | (885) |  |
| Repayment of convertible debt | (5229) |  |
| Contingent consideration payment |  | (1818) |
| &nbsp;&nbsp;**Net cash provided by (used in) financing activities** | $(9162) | $(12325) |

---

The cash used in financing activities for the nine months ended September 30, 2025 was related to cash used to settle taxes related to employee equity programs, settlement of the 2027 Notes, and debt issuance costs associated with the execution of the Fourth Amendment of the Loan and Security Agreement, partially offset by cash received under the Employee Stock Purchase Plan. The cash used in financing activities for the nine months ended September 30, 2024 was related to cash used to settle taxes related to employee equity programs and contingent consideration payment related to Epiluvac acquisition, partially offset by cash received under the Employee Stock Purchase Plan.

*Convertible Senior Notes*

We have $230.0 million outstanding principal balance of convertible senior notes that bear interest at a rate of 2.875% per year, payable semiannually in arrears on June 1 and December 1 of each year, and mature on June 1, 2029, unless earlier purchased by the Company, redeemed, or converted.

We believe that we have sufficient capital resources and cash flows from operations to support scheduled interest payments on this debt. In addition, in June 2025, we increased the total funds available to us through our revolving credit facility from $225 million to $250 million and extended the maturity until June 16, 2030, subject to a springing maturity date of March 2, 2029. The Company has no immediate plans to draw down on the facility. Interest under the facility is variable based on the Company's secured net leverage ratio and is expected to bear interest based on SOFR plus a range of 125 to 200 basis points, if drawn. There is a yearly commitment fee of 20 to 30 basis points, based on the Company's secured net leverage ratio, charged on the unused portion of the Facility.

In connection with the Merger, the convertible senior notes will be assumed by Axcelis.

*Contractual Obligations and Commitments*

We have commitments under certain contractual arrangements to make future payments for goods and services. These contractual arrangements secure the rights to various assets and services to be used in the future in the normal course of business. We expect to fund these contractual arrangements with cash generated from operations in the normal course of business.

[**Table of Contents**](#TOC)

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

*Interest Rate Risk*

Our exposure to market rate risk for changes in interest rates primarily relates to our investment portfolio. We centrally manage our investment portfolios considering investment opportunities and risks, tax consequences, and overall financing strategies. Our investment portfolio includes fixed-income securities with a fair value of approximately $176.1 million at September 30, 2025. These securities are subject to interest rate risk and, based on our investment portfolio at September 30, 2025, a 100 basis point increase in interest rates would result in a decrease in the fair value of the portfolio of $1.2 million. While an increase in interest rates may reduce the fair value of the investment portfolio, we will not realize the losses in the Consolidated Statements of Operations unless the individual fixed-income securities are sold prior to recovery or the loss is determined to be other-than-temporary.

*Currency Exchange Risk*

We conduct business on a worldwide basis and, as such, a portion of our revenues, earnings, and net investments in foreign affiliates is exposed to changes in currency exchange rates. The economic impact of currency exchange rate movements is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions, and other factors. These changes, if material, could cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.

Changes in currency exchange rates could affect our foreign currency denominated monetary assets and liabilities and forecasted cash flows. We may enter into monthly forward derivative contracts from time to time with the intent of mitigating a portion of this risk. We only use derivative financial instruments in the context of hedging and not for speculative purposes and have not historically designated our foreign exchange derivatives as hedges. Accordingly, changes in fair value from these contracts are recorded as "Other, net" in our Consolidated Statements of Operations. We execute derivative transactions with highly rated financial institutions to mitigate counterparty risk.

Our net sales to customers located outside of the United States represented approximately 84% and 85% of our total net sales for the three and nine months ended September 30, 2025, respectively, 68% and 76% for the comparable 2024 period. We expect that net sales to customers outside the United States will continue to represent a large percentage of our total net sales. Our sales denominated in currencies other than the U.S. dollar represented approximately 3% and 5% of total net sales for the three and nine months ended September 30, 2025, respectively, and 4% for both the comparable 2024 period.

A 10% change in foreign exchange rates would have an immaterial impact on the consolidated results of operations since most of our sales outside the United States are denominated in U.S. dollars.

[**Table of Contents**](#TOC)

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures*

Our principal executive and financial officers have evaluated and concluded that our disclosure controls and procedures are effective as of September 30, 2025. The disclosure controls and procedures are designed to ensure that the information required to be disclosed in this report filed under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to our principal executive and financial officers as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control Over Financial Reporting*

During the quarter ended September 30, 2025, there were no changes in internal control that have materially affected or are reasonably likely to materially affect internal control over financial reporting.

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings**

The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.

**Item 1A. Risk Factors**

Information regarding risk factors appears in the Safe Harbor Statement at the beginning of this quarterly report on Form 10-Q, in Part I — Item 1A of our 2024 Form 10-K and in Item 1A of our quarterly reports on Form 10-Q for quarters ended March 31, 2025 and June 30, 2025. Except as set forth below, there have been no material changes from the risk factors previously disclosed.

**Risks Related to the Merger**

***The Merger is subject to certain closing conditions, including the receipt of consents and approvals from governmental authorities, which may impose unexpected delays in the completion of the Merger, or the Merger may not be completed at all.***

The Merger is currently expected to close during the second half of 2026, assuming that all of the conditions in the Merger Agreement are satisfied or waived. The Merger Agreement provides that either we or Axcelis may terminate the Merger Agreement if the Merger has not occurred by September 30, 2026 (subject to automatic extensions until as late as June 30, 2027 under certain conditions with respect to the receipt of regulatory approvals). Certain events may delay the completion of the Merger or result in a termination of the Merger Agreement. Some of these events are outside the control of either party. In particular, completion of the Merger requires the receipt of various government approvals, the expiration or termination of the applicable antitrust waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the adoption of the Merger Agreement by our and Axcelis' respective stockholders at our and Axcelis' respective special meetings of stockholders.

If the required vote is not obtained at either special meeting (including any adjournment or postponement thereof) at which the Merger has been voted upon, either we or Axcelis may terminate the Merger Agreement. If the Merger Agreement is terminated by Axcelis following a recommendation change of our board of directors, we will be required to pay a termination fee of $77,500,000 to Axcelis. In addition, if the Merger Agreement is terminated by Axcelis as a result of our failure to obtain stockholder approval, or is terminated by Axcelis due to our breach of the Merger Agreement that would result in a failure of an applicable closing condition (subject to the applicable cure period set forth in the Merger Agreement), then the we will be required to pay a fixed expense reimbursement amount of $15,000,000.

[**Table of Contents**](#TOC)

We may incur significant additional costs in connection with any delay in completing the Merger or termination of the Merger Agreement, in addition to significant transaction costs, including legal, financial advisory, accounting and other costs we have already incurred. We cannot provide any assurance that the conditions to the completion of the Merger will be satisfied or waived or that any adverse change, effect, event, circumstance, occurrence or state of facts that could give rise to the termination of the Merger Agreement will not occur, and we cannot provide any assurances as to whether or when the Merger will be completed on the terms or timeline set forth in the Merger Agreement or at all.

***Failure to complete the Merger in a timely manner or at all could materially and adversely affect our stock price and future business and financial results.***

We can provide no assurance that the Merger will occur or that the conditions to the Merger will be satisfied in a timely manner or at all. Also, we can provide no assurance that an event, change or other circumstance that could give rise to the termination of the Merger Agreement will not occur. Delays in completing the Merger or the failure to complete the Merger at all could materially and adversely affect our future business and financial results, and, in that event, the market price of our common stock may decline significantly, particularly to the extent that the current market price reflects a market assumption that the Merger will be completed. If the Merger is delayed for any reason, we will be subject to several risks, including the diversion of management focus and resources from operational matters and other strategic opportunities while working to complete the Merger, any of which could materially and adversely affect our business, financial condition, results of operations, cash flows, and stock price.

***The pendency of the Merger could materially and adversely affect our business and operations.***

In connection with the pending Merger, some of our current or prospective customers, suppliers and other vendors, lenders or other business counterparties may delay or defer decisions concerning their business relationships or transactions with us, which could negatively impact our sales and revenue generation, margins, operating expenses, and profitability, regardless of whether the Merger is completed. In addition, under the Merger Agreement, we are restricted from entering into certain corporate transactions and taking certain other specified actions, and requires that we conduct our business in all material respects in the ordinary course and consistent with past practice until the completion of the Merger or the termination of the Merger Agreement. These restrictions, which could be in place for an extended period of time if the completion of the Merger is delayed, could prevent us from pursuing attractive business opportunities that may arise prior to completion of the Merger or from making appropriate changes to business or organizational structure. This could in turn materially and adversely impact our business, financial condition and results of operations.

The pendency of the Merger may also make it more difficult for us to effectively recruit, retain and incentivize key personnel and may cause distractions from our strategy and day-to-day operations for our current employees and management. Further, uncertainty about the effect of the Merger on our employees may have a material adverse effect on us during the pendency of the Merger, as this uncertainty may impair our ability to retain and motivate key personnel during the pendency of the Merger and the combined company's ability to retain and motivate them following the Merger. Employee retention may be particularly challenging as our employees may experience frustration during the integration process and uncertainty about their future roles following consummation of the Merger.

***Because the consideration to be received by our stockholders in connection with the Merger will include a fixed number of shares of Axcelis common stock, and the market price of such shares has fluctuated and will continue to fluctuate, our stockholders cannot be sure of the value of the consideration they will receive in the Merger.***

Under the Merger Agreement, at the effective time of the Merger, each share of Veeco common stock (other than each share of Veeco common stock held in treasury or held or owned by Veeco, Axcelis or Merger Sub immediately prior to the effective time of the Merger) issued and outstanding immediately prior to the effective time of the Merger will be cancelled and converted into the right to receive 0.3575 newly issued shares of Axcelis common stock. The market value of the consideration our stockholders will receive in the Merger will therefore fluctuate with the market price of Axcelis common stock. The implied value of the Merger Consideration has fluctuated since the date of the announcement of the Merger Agreement and will continue to fluctuate until the date the Merger is completed, which could occur a considerable amount of time after the date hereof.

[**Table of Contents**](#TOC)

Prior to the completion of the Merger, the market price of Axcelis common stock, along with short selling activity in both our common stock and Axcelis common stock, has and is expected to continue to impact the market price our common stock. The value of the merger consideration to be received by our stockholders has fluctuated since the date of the announcement of the Merger Agreement and will continue to fluctuate until the Merger is completed and thereafter. Accordingly, at the time of our special meeting, our stockholders will not know or be able to determine the market value of the consideration they would receive upon completion of the Merger. Stock price changes may result from a variety of factors, including, among others, interest rates, general market, industry, economic and geopolitical conditions, including the impact of continued inflation and associated changes in monetary policy, short-selling activity, changes in and speculation regarding our and Axcelis' respective businesses, operations and prospects, market assessments of the likelihood that the Merger will be completed, the timing of the Merger and regulatory considerations. Many of these factors are beyond our and Axcelis' control.

***Under Delaware law, our stockholders are not entitled to an appraisal of the fair value of their shares in connection with the Merger.***

Under Delaware law, holders of our common stock are not entitled to an appraisal of the fair value of their shares in connection with the Merger. Appraisal rights are statutory rights that enable stockholders to dissent from certain extraordinary transactions, such as certain mergers, and to demand that the corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the consideration offered to stockholders in connection with the applicable transaction. Under Delaware law, appraisal rights are not available for the shares of any class or series if the shares of the class or series are listed on a national securities exchange or held of record by more than 2,000 holders on the record date, unless the stockholders receive in exchange for their shares anything other than shares of stock of the surviving or resulting corporation or of any other corporation that is publicly listed or held by more than 2,000 holders of record, cash proceeds from the sale of fractional shares or fractional depositary receipts or any combination of the foregoing. Our common stock is listed on the Nasdaq, and our stockholders will receive Axcelis common stock pursuant to the Merger Agreement and cash proceeds from the sale of fractional shares.

***The market price of Axcelis common stock after the Merger may be affected by factors different from those affecting the market price of our common stock.***

Upon completion of the Merger, holders of Veeco common stock will become holders of shares of Axcelis common stock. Our business differs from that of Axcelis in important respects, and, accordingly, the results of operations of Axcelis after the Merger, as well as the market price of Axcelis common stock, may be affected by factors different from those currently affecting our results of operations. Additionally, the market price of Axcelis common stock may fluctuate significantly following completion of the Merger.

***Our current stockholders will have a reduced ownership interest and voting power in the combined company after the Merger.***

Immediately following the Merger, our pre-Merger stockholders are expected to hold approximately 41.6% of the combined company's common stock and the pre-Merger stockholders of Axcelis are expected to hold approximately 58.4% of the combined company's common stock, in each case, calculated on a fully diluted basis.

Our stockholders and Axcelis' stockholders currently have the right to vote for their respective directors and on certain other matters affecting their respective companies. If and when the Merger occurs, each Veeco stockholder who receives shares of Axcelis common stock will become an Axcelis stockholder with a percentage ownership of Axcelis that will be smaller than the stockholder's current percentage ownership of Veeco (without considering such stockholder's current ownership of our common stock, if any). Accordingly, our pre-Merger stockholders will have less voting power in us than they now have in Veeco and will be able to exercise less influence over the management and policies of the combined company following the consummation of the Merger than they are able to exercise over Veeco immediately prior to the consummation of the Merger.

[**Table of Contents**](#TOC)

***An adverse judgment in a lawsuit challenging the Merger may prevent the Merger from becoming effective or from becoming effective within the expected timeframe.***

Our stockholders may file lawsuits challenging the Merger or the other transactions contemplated by the Merger Agreement, which may name us and/or our board of directors as defendants. We cannot provide any assurance as to the outcome of such lawsuits, including the amount of costs associated with defending these claims or any other liabilities that may be incurred in connection with the litigation of these claims. One of the conditions to the completion of the Merger is that no injunction by any governmental entity of competent jurisdiction, such as a court, is in effect that prohibits, restrains or makes illegal the consummation of the Merger. As such, if any future legal actions result in an injunction prohibiting the consummation of the Merger, then such injunction may prevent the consummation of the Merger on the agreed terms, within the expected timeframe or at all, any of which could substantially harm our business. Whether or not any plaintiff's claim is successful, this type of litigation may result in significant costs and divert management's attention and resources, which could materially and adversely affect the operation of our business.

***We are expected to incur significant costs in connection with the Merger and integration of the two companies, which may be in excess of those anticipated by us.***

We have incurred and expect to continue to incur costs associated with negotiating and completing the Merger and combining the operations of the two companies. These costs have been, and will continue to be, substantial. The substantial majority of costs will consist of transaction costs related to the Merger and include, among others, fees paid to financial, legal and accounting advisors, filing fees, and employee retention and other employment-related costs. Many of these costs will be borne by us even if the Merger is not completed.

We will also incur transaction costs related to formulating and implementing integration plans, including facilities, systems and service contract consolidation costs and employment-related costs. We will continue to assess the magnitude of these costs, and additional unanticipated costs may be incurred in connection with the Merger and the integration of the two companies' businesses. Although we expect that the elimination of duplicative costs, as well as the realization of other synergies related to the integration of the businesses, should allow the combined company to offset integration-related costs over time, this net benefit may not be achieved in the near term, or at all. The costs described above, as well as other unanticipated costs and expenses, could materially and adversely affect the results of operations, financial condition and cash flows of the combined company following the completion of the Merger.

***The Merger Agreement contains provisions that limit our ability to pursue alternatives to the Merger, which could discourage a potential competing acquiror from making an alternative transaction proposal for greater consideration that what Axcelis has agreed to pay in the Merger.***

The Merger Agreement contains provisions that preclude our ability to pursue alternatives to the Merger and require us to refrain from soliciting, initiating or knowingly encouraging or knowingly inducing, or taking any other action intentionally designed to facilitate, any inquiries or the making of any competing proposals from third parties or to engage in discussions or negotiations with third parties regarding any competing proposals, subject to certain exceptions. With respect to any unsolicited written, bona fide acquisition proposal that we receive, if it is deemed to be a superior proposal, Axcelis generally has an opportunity to offer to modify the terms of the Merger Agreement in response to such proposal before our board of directors may withdraw or modify its recommendation to stockholders in response to such acquisition proposal or terminate the Merger Agreement to enter into a definitive agreement with respect to such acquisition proposal. Upon termination of the Merger Agreement under circumstances relating to a superior proposal, we may be required to pay a termination fee of $77,500,000 to Axcelis depending on the circumstances giving rise to the termination, which likely would discourage a potential third-party merger partner from making an alternative transaction proposal, even if it were prepared to pay consideration with a higher value than implied in the Merger, or cause such third-party to propose to pay a lower price than it might otherwise have proposed to pay because of the added expense of the termination fee.

Additionally, if the Merger Agreement is terminated and we determine to seek another business combination, we may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the Merger.

[**Table of Contents**](#TOC)

***Directors and officers of Veeco may have interests in the Merger that may be different from, or in addition to, those of other our other stockholders, which could have influenced their decisions to support or approve the Merger.***

Certain of our directors and officers have interests in the Merger that may differ from, or that are in addition to, their interests as our stockholders. William J. Miller, Ph.D., our Chief Executive Officer and a member of our board of directors, and certain other members of our board of directors, will continue as directors of the combined company after the consummation of the Merger, and will be eligible to be compensated as non-employee directors of the combined company. In addition, Dr. Miller, together with certain other Company officers, will be entitled to cash severance payments, certain health insurance coverage and the acceleration of outstanding equity awards in the event of an involuntary termination in connection with a change of control of Veeco. Our board of directors (except for one (1) independent director who serves on the boards of both Axcelis and Veeco and thus recused himself) were aware of these interests at the time they approved the Merger Agreement. These interests may cause Dr. Miller and certain of our directors and officers to view the Merger differently than you may view it as a stockholder.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not Applicable.

**Item 5. Other Information**

None.

[**Table of Contents**](#TOC)

**Item 6. Exhibits**

Unless otherwise indicated, each of the following exhibits has been filed with the Securities and Exchange Commission by Veeco under File No. 0-16244.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| **Exhibit**<br>**Number** | <br>**Exhibit Description** | **Form** | **Exhibit** | **Filing Date** | **Filed or**<br>**Furnished**<br>**Herewith** |
| 2.1 | [Agreement and Plan of Merger, dated as September 30, 2025, by and among Axcelis Technologies, Inc., Veeco Instruments Inc. and Victory Merger Sub, Inc.](https://www.sec.gov/Archives/edgar/data/103145/000110465925095312/tm2527554d1_ex2-1.htm) | 8-K | 2.1 | 10/01/2025 |  |
| 10.1 | [Fifth Amendment to Loan and Security Agreement, dated as of September 30, 2025, by and among Veeco Instruments Inc., as borrower, the guarantors party thereto, HSBC Bank USA, National Association, as administrative agent and collateral agent, and the lenders from time to time party thereto.](https://www.sec.gov/Archives/edgar/data/103145/000110465925095312/tm2527554d1_ex10-1.htm) | 8-K | 10.1 | 10/01/2025 |  |
| 31.1 | [Certification of Chief Executive Officer pursuant to Rule 13a—14(a) or Rule 15d—14(a) of the Securities and Exchange Act of 1934.](veco-20250930xex31d1.htm) |  |  |  | \* |
| 31.2 | [Certification of Chief Financial Officer pursuant to Rule 13a—14(a) or Rule 15d—14(a) of the Securities and Exchange Act of 1934.](veco-20250930xex31d2.htm) |  |  |  | \* |
| 32.1 | [Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002.](veco-20250930xex32d1.htm) |  |  |  | \* |
| 32.2 | [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002.](veco-20250930xex32d2.htm) |  |  |  | \* |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  | \*\* |
| 101.XSD | XBRL Schema. |  |  |  | \*\* |
| 101.PRE | XBRL Presentation. |  |  |  | \*\* |
| 101.CAL | XBRL Calculation. |  |  |  | \*\* |
| 101.DEF | XBRL Definition. |  |  |  | \*\* |
| 101.LAB | XBRL Label. |  |  |  | \*\* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |  |  |  | \*\* |

---

\*&nbsp;&nbsp;&nbsp;&nbsp; Filed herewith

\*\* Filed herewith electronically

[**Table of Contents**](#TOC)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 5, 2025.

---

| | |
|:---|:---|
| Veeco Instruments Inc. | Veeco Instruments Inc. |
| By: | /s/ WILLIAM J. MILLER, Ph.D. |
|  | William J. Miller, Ph.D. |
|  | *Chief Executive Officer* |
| By: | /s/ JOHN P. KIERNAN |
|  | John P. Kiernan |
|  | *Senior Vice President and Chief Financial Officer* |

---

## Exhibit 31.1

**Exhibit 31.1**

CERTIFICATION PURSUANT TO

RULE 13a — 14(a) or RULE 15d — 14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, William J. Miller, Ph.D., certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2025 of Veeco Instruments Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| By: | /s/ WILLIAM J. MILLER, Ph.D. |
|  | William J. Miller, Ph.D. |
|  | Chief Executive Officer |
|  | Veeco Instruments Inc. |
|  | November 5, 2025 |

---

------

## Exhibit 31.2

**Exhibit 31.2**

CERTIFICATION PURSUANT TO

RULE 13a — 14(a) or RULE 15d — 14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, John P. Kiernan, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2025 of Veeco Instruments Inc.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| By: | /s/ JOHN P. KIERNAN |
|  | John P. Kiernan |
|  | Senior Vice President and Chief Financial Officer |
|  | Veeco Instruments Inc. |
|  | November 5, 2025 |

---

------

## Exhibit 32.1

**Exhibit 32.1**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Veeco Instruments Inc. (the "Company") on Form 10-Q for the period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, William J. Miller, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ WILLIAM J. MILLER Ph.D. |
|  | William J. Miller, Ph.D. |
|  | Chief Executive Officer |
|  | Veeco Instruments Inc. |
|  | November 5, 2025 |

---

A signed original of this written statement required by Section 906 has been provided to Veeco Instruments Inc. and will be retained by Veeco Instruments Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------

## Exhibit 32.2

**Exhibit 32.2**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Veeco Instruments Inc. (the "Company") on Form 10-Q for the period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John P. Kiernan, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ JOHN P. KIERNAN |
|  | John P. Kiernan |
|  | Senior Vice President and Chief Financial Officer |
|  | Veeco Instruments Inc. |
|  | November 5, 2025 |

---

A signed original of this written statement required by Section 906 has been provided to Veeco Instruments Inc. and will be retained by Veeco Instruments Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------